Description of clinical and pathological features of MFM caused by Desmin mutations.
1. Introduction
Myofibrillar myopathies (MFMs) are typically autosomal dominant myopathies with late onset progressive muscle weakness and symptoms initially evident in the distal muscle groups. However, there is a significant variability in the presentation of these diseases, with the age of onset ranging from infantile to late seventies; the involvement of the heart, respiratory muscles, distal or proximal muscle groups; and severity covering the full spectrum from mild muscle weakness to premature lethality. Several myopathies were identified with symptoms within this broad spectrum and the recognition of a common pathology allowed the grouping of these diseases under a single term, MFM [1]. Problems in the classification of these disorders still exist, partially due to the wide spectrum of clinical presentation and the lack of detailed analysis of biopsy samples to identify the defining features of MFM.
The defining features of MFM, identified using histological stains and electron microscopy, are the dissolution of muscle fibres and the formation of protein aggregates. Common pathological features of MFM include presence of amorphous, granular, filamentous or hyaline deposits, interstitial fibrosis, fatty infiltration, centrally located nuclei indicative of regeneration, necrosis and muscle degeneration. Displaced membranous organelles are also evident, either in the cytoplasm or within autophagic vacuoles. Affected areas of the cells are frequently devoid of oxidative enzymatic activity and mitochondria can be abnormally shaped and positioned [2-5]. Characterization of the protein aggregates using immunohistochemistry reveals the presence of a wide range of sarcomeric, extracellular, and ubiquitously expressed proteins including Myotilin, Desmin, αB-Crystallin, Filamin C, BAG3, ZASP, Actin, Titin, Myosin, Xin, Dystrophin, sarcoglycans, Plectin, Delsolin, Ubiquitin, Neural cell adhesion modulator, Gelsolin, Syncoilin, Synemin, TAR DNA-binding protein 43, Heat-shock protein 27, and DNAJB2 [6]. Interestingly, α-Actinin, which is the primary Z-disk crosslinker and is associated with many of the Z-disk proteins mutated in MFM, is not detected in these protein aggregates [6,7].
The Z-disk provides an important structural linkage in the transmission of tension and contractile forces along the muscle fibre and has a role in sensing of muscle activity and signal transduction. In line with the identification of the Z-disk as the primary site affected in these myopathies the identification of MFM causing mutations has revealed a very strong association with the Z-disk, with all of the proteins affected being localised to this structure. Mutations have been identified in the intermediate filament (IF) protein Desmin [8], the chaperone αB-Crystallin [9], the structural protein Myotilin [10], the α-Actinin binding protein ZASP[11], the actin binding protein Filamin C[12], and the co-chaperone BAG3[13]. Based on the Mayo Clinic MFM cohort, 14% of MFMs are due to mutations in ZASP, 13% due to Myotilin mutations, 8% Desmin mutations, 5% αB-Crystallin mutations, 4% BAG3 mutations, and 4% due to mutations in Filamin C, with the genetic basis of more than 50% of MFM cases remaining unknown [14].
Whilst subtle differences in morphology and histochemical staining are found to be associated with certain MFM subtypes [3], they are not reliable in identifying the genetic cause of MFM. Ultrastructural studies on the other hand have been shown to be more informative in identifying the subtype of MFM, although repetition with large sample sizes is required to determine the reliability of ultrastructure studies is directing diagnosis[15].
Mutations in any of the identified MFM genes can also result in other forms of myopathy including dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), distal myopathy, spheroid body myopathy (SBM), and limb-girdle muscular dystrophy (LGMD). Whilst mutations can result in different myopathies, within the cases of MFM there is a remarkable consistency in the phenotype regardless of the gene mutated. This unifying pathological presentation suggests a common mechanism of pathology, although the functions of the MFM proteins and how their mutation results in disease are not fully understood. Determination of the mechanism by which these mutation result in disease will not only be important for the development of therapies for these conditions but will also provide insight into the role of these proteins in the muscle and the many functions of the Z-disk. We present an analysis of the literature surrounding each of these proteins and how their mutations result in disease and discuss the implications for MFM and Z-disk function.
2. Desmin and desminopathies
Desmin, named from the word ‘desmos’ which means ‘link’ is a small, 53KDa, IF protein found in skeletal, smooth [16], and cardiac [17] muscle cells. In mature skeletal muscle, Desmin along with other Desmin-binding molecules such as Plectin, links adjacent myofibrils at the Z-disk and binds them to the sarcolemma at the costameric level [18]. Desmin localisation to the intermediate filament, Z-disk, and costamere provides a cytoskeletal network that links the contractile apparatus to the cell membrane and other structural elements of the cell, which is critical for maintaining the integrity of the cell, ensuring force transmission and providing with a pathway for signalling. In order to form a fully functional IF network Desmin connects with different cell structures from the cell membrane to the nuclear envelope. Therefore Desmin interacts with a range of different muscle, non-muscle, and nuclear proteins. At the Z-disk, it interacts with αB-Crystallin (CRYAB) [19] and Nebulin [20,21]. At the periphery of the Z-disk, costameres, nucleus, and neuromuscular junctions Desmin interacts with Vimentin, Synemin [22], Paranemin [23], Desmulsin [24], Lamin [25], Plectin [26], Nestin [27], spectrins [28], and Ankyrin [29]. Deficiency in Desmin not only results in disturbance to the structure of the sarcomere, but also results in striking changes to the cellular morphology, which may have direct implications for muscle function. Desmin knockout mice show abnormal mitochondrial localization, accompanied by an increase in number and size, a rounded shape and distorted membranes, often showing granules and even mineralised bodies [30].
Structurally, Desmin is made up of three domains; an N-terminal head domain, a highly conserved central α-helical core, and a C-terminal tail domain (Figure 1). The central α-helical core, a region responsible for Desmin assembly into IF, is made up of four consecutive helical segments, 1A, 1B, 2A and 2B, which are linked by short non helical linkers [31,32]. These helical domains are made of tandem repeats of a specific seven amino acid sequence that contains the biochemical properties that allow the proper coiling of the protein. Additionally, the 2B helical domain contains a four amino acid insertion, known as the ‘stutter’, critical for Desmin assembly and conserved between many IF proteins [33,34]. Of the 50 Desmin mutations reported so far that result in severe skeletal and/or cardiac muscle defects the majority affect the coiled domains, five affect the head domain and eleven affect the tail domain (Figure 1). Interestingly, no mutations in domain 2A have been reported to date and more than 50% of reported Desmin mutations are in the 2B domain [35]. Although a correlation between the domain mutated and the clinical features of the patients/carriers has been suggested (reviewed in [35]), when the clinical features are analysed in more detail the only correlation that appears to be maintained is the predominance of skeletal muscle defects in patients with mutations in the 2B domain (Table 1 and Table 2).
Mutations are coloured accordingly to the disease classification. Note that 3’UTR is not drawn to scale. Mutations are coloured accordingly to the disease classification. Note that 3’UTR is not drawn to scale.
c.5G"/>T | ?Skel | [36,37] | |
c.137C"/>T | ? | [36,37] | |
c.137C"/>A | ? | [36,37] | |
c.430A"/>T | 37Card | [38] | |
c.640-2A"/>C? (exon 3 skipping) | 26-32Card | [38] | |
c.1006G"/>T | 37Card | [38] | |
c.1315G"/>A | 51Card | [38] | |
c.1325C"/>T | 27-35Skel | [39] | |
c.1346A"/>C | 14Skel | [36,39] | |
c.1360C"/>T | 15Card | [39,40] | |
c.1379G"/>T | 29Card | [39] | |
c.1413A"/>C | 35Card | [38] |
c.38C"/>T | DRM | [37,41-43] | |
c.46C"/>T* | RCM | [37,44] | |
c.322G"/>A | DCM | [45] | |
c.338A_339Gdel | DRM | [46] | |
c.517_537del* | DRM | [47,48] | |
c.638C"/>T (+α-glucosidase mutation) | DRM | [49,50] | |
c.639-1G"/>A + c.735+2A"/>G | DRM | [44,51-53] | |
c.719dupA | distal myopathy | [54] | |
c.735G"/>C/T | distal myopathy | [49,53,55] | |
c.893C"/>T | DCM | [45] | |
c.934G"/>A | DCM | [45] | |
c.1009G"/>C | DCM | [49,50,52,56,57] | |
c.1013T"/>G | DRM | [50] | |
c.1024A"/>G | DRM | [43,49,52] | |
c.1034T"/>C | DRM | [8,49,58,59] | |
c.1049G"/>C | distal myopathy and CM | [60] | |
c.1048C"/>T | DCM | [45] | |
c.1064C"/>G | DRM | [61] | |
c.1069G"/>C | DRM | [49,62] | |
c.1075_1083del | DRM | [63] | |
c.1078G"/>C* | DRM | [49,52,56] | |
c.1097_1099del | DRM | [63,64] | |
c.1099A"/>T | DRM | [65] | |
c.1109T"/>C | DRM | [49,62,66] | |
c.1130T"/>C | DRM | [67] | |
c.1154T"/>C | DRM | [49,68] | |
c.1166A"/>C | DRM | [49,69] | |
c.1175T"/>C | DRM | [65] | |
c.1178A"/>T* | DRM | [49,50,52,56] | |
c.1195G"/>T | DRM | [49,50] | |
c.1201G"/>A | DRM | [50] | |
c.1216C"/>T | DRM | [44,49,52,65,69,70] | |
c.1237G"/>A | DRM | [39,49,71] | |
c.1255C"/>T | DRM | [65] | |
c.1353C"/>G | DRM | [52,72-74] | |
c.1358C"/>T | DRM | [44] | |
c.1375G"/>A | DCM | [45] | |
c.1405G"/>A | DCM | [37,41-43] |
Mutations in Desmin result in many different myopathies (Table 1 and Table 2). Desmin-related myopathies (DRM) is a term that has been used to describe myopathies due to mutations in Desmin and CRYAB including MFMs, here we only use it to refer to those caused by Desmin mutations. In addition to the broad spectrum of DRM, Desmin mutations have also been classified as MFM, distal myopathy, DCM, and RCM (see Table 1 and Table 2). Some of the DRMs may be examples of MFM but without further information it is not possible to re-classify them as MFMs. There is significant cardiac involvement in many Desmin myopathies and in some cases individuals with the same mutation may initially present with cardiac or skeletal muscle symptoms suggesting there is significant phenotypic variability and the possibility of modifiers of the Desmin myopathies. For example, the I451M mutation has been reported in a case of familial DCM without skeletal muscle phenotypes [72] and in individuals with skeletal myopathy without any evident cardiac defect [74]. Furthermore, the mutation was not fully penetrant in the family with DCM [72]. Potential modifiers include -Glucosidase, with a single individual identified as a compound heterozygote for -Glucosidase missense mutations and heterozygous for the Desmin A213V mutation displaying progressive muscle weakness not evident in related individuals carrying A213V alone [50], and Lamin A, as identified in an individual with Emery Dreifuss muscular dystrophy due to heterozygous Lamin A and Desmin V469M mutations [75].
Mutations in Desmin may also affect its capability to interact with its binding partners. Indeed, analysis of mutant protein E245D using solid phase binding assays showed that it binds to Nebulin with increased affinity, reducing Nebulin at the Z-disk, and is more prone to aggregate formation [76]. This interferes with Nebulin’s ability to regulate the thin filament and results in disease [76]. Furthermore, the targeted mutation K190A, not yet observed in disease, shows decreased affinity for Nebulin resulting in decreased targeting of Nebulin to the Z-disk, its accumulation in aggregates in both skeletal and cardiac muscle, and narrower Actin bundles. It was therefore hypothesised that the lack of functional Desmin prevents Nebulin from stabilising Actin thin filaments thereby resulting in collapse of the contractile apparatus [21].
To study the role of Desmin in muscle function two independent knockout mice lines were created [77,78]. Both lines develop normally, are viable and fertile, with no defects in myogenesis. However, they present postnatal multisystem disorder, decreased myofibril alignment, defects in nuclear and mitochondrial positioning within the cell, and severe cardiac degeneration [77-81]. Muscle of
It has been extensively suggested that Desmin may be essential in lateral force transmission by connecting adjacent sarcomeres, and even neighbouring myofibres, by costamere-extracellular matrix (ECM) binding. Therefore, Desmin mutations may impair its ability to respond to applied strain. Studies on Desmin with tail domain mutations in which the filament assembly is normal in both
The analysis of filament formation
3. B-crystallin and B-crystallinopathies
To date 15 mutations in CRYAB have been reported. CRYAB belongs to the small Heat shock family of proteins (sHSP). It interacts with A-Crystallin (CRYAA) via non-covalent bonds to form large heterogeneous macromolecular complexes [19]. Both CRYAA and CRYAB are found in high levels in the lens tissue of the eye where they are involved in maintaining lens transparency and refractive index [84]. CRYAB is also found in significant amounts in non-lenticular tissues such as skeletal and cardiac muscle, the kidney, and the brain [85-87]. In skeletal muscle CRYAB expression is highest in the oxidative slow twitch muscle and lowest in the glycolytic fast muscle [85,88]. In skeletal and cardiac muscle CRYAB is localised to the Z-disk [89] where it interacts with the I-band protein Actin [19] and various IF proteins including Desmin [19], Vimentin [90], and Glial fibrillary acidic protein(GFAP) [91].
The N-terminal globular domain and the highly conserved C-terminal ‘-crystallin domain’ (ACD; Figure 2) of CRYAB are critical for its chaperone-like function [92-94] and dimerisation [95]. CRYAB prevents stress induced aggregation of various proteins including β- and γ-Crystallins [93,93], Desmin [19], Vimentin [90], and GFAP [91]. Following stressful conditions such as osmotic stress, metal toxicity [96], serum starvation, hypertonic stress, and heat shock [90] CRYAB expression is up-regulated and recruited to the IF to remodel the IF network [90]. Mutations in CRYAB have been shown to interfere with both its dimerisation and chaperone functions. Resolution of the crystal structure of the MFM causing R120G mutant protein showed a disruption to its tertiary structure predicted to interfere with its dimerisation and result in the formation of large soluble oligomers [97]. Moreover, the ACD domain of mutant CRYAB adopts an irregular structure, which decreases its chaperone function, makes it unstable and promotes its aggregation [98-100]. The mutant CRYAB has also been shown to have a higher dissociation constant, which prevents its dissociation from Desmin [101] resulting in Desmin containing aggregates as seen in MFM [100,101]. Therefore, alterationsin the structure of CRYAB, its inability to perform its chaperone functions, and disruptionof its interaction with its binding partners all contribute to disease pathology. In contrast to other MFM genes there does appear to be some correlation between genotype and phenotype with mutations in exon one resulting in isolated cataracts whilst exon three mutations can result in cataracts [102-107], MFM [108-110], distal myopathy [111],and/or CM [112,113], with two mutations resulting in both cataract formation and muscle failure [114,115] (Table 3).
Following contraction CRYAB is phosphorylated and translocates from the cytoplasm to the Z-disk which is thought to allow CRYAB mediated repair or protection of the Z-disk [125]. Recently, a rare case of infantile onset MFM was identified due to a homozygous frameshift mutation, S115fsX14, resulting in muscle stiffness [110]. The authors suggest the mutation results in a loss of contraction timulated translocation to the Z-disk and consequent reduction in muscle repair. CRYAB has also been implicated in indirectly preventing apoptosis and autophagy, inhibiting Caspase 3 mediated [126], Ras induced[127], and Bcl-2 mediated apoptosis [128]. It is therefore not surprising that CRYAB deficiency results in decreased cell viability and an increase in apoptosis in CRYAB knock-out mouse [129] and in patients suffering with CRYAB mutations [108]. In basal breast cancer CRYAB behaves as an oncoprotein [130] and in highly migratory glioma cells prevents apoptosis [131] making it a potential target in cancer therapy. Up-regulation of CRYAB may be part of a general protective mechanism since CRYAB is up-regulated in various pathological conditions such as cardiac ischemia [132], multiple sclerosis [133], Alzheimer’s [134], and other neurodegenerative disorders [84].
Wildtype CRYAB has the capability to bind to mutant protein to prevent its aggregation. For example, transfection of the MFM causing R120G mutant CRYAB into PtK2 cells results in the formation of aggregates but co-transfection with wildtype CRYAB, or the chaperone molecule Hsp27, results in a significant decrease in the amount of insoluble R120G CRYAB present in the cell and the frequency of aggregate formation [135]. Recently the BAG3 co-chaperone protein has also been shown to co-oligomerise with mutant CRYAB to suppress its aggregation and toxicity [136]. This does highlight that stimulating an increase in wildtype CRYAB, Hsp27, or BAG3 may be sufficient to prevent the formation of protein aggregates.
The observation that there is a 10 fold increase in CRYAB expression in differentiating and proliferating myoblasts [137,138] suggests that CRYAB may play a role in regulating myogenesis. CRYAB has been shown to decrease the synthesis, and increase the degradation, of MyoD, a myogenic regulatory factor that specifies cell lineage, resulting in delayed differentiation. Additionally, up-regulation of CRYAB in muscle cells results in sustained expression of cell cyclemarkers such as Cyclin D1 indicating cells were more proliferative [139]. Therefore, CRYAB can influence myogenesis by altering MyoD levels and cell cycle exit. Despite the potential for CRYAB to regulate muscle differentiation CRYAB knockout mice have normal muscle at birth but present with severe muscular dystrophy by week 40 suggesting CRYAB is not critical for muscle development but is essential for muscle function [129].
Age of onset / Initial symptoms | |||
c.61delA* | Birth-11 weeks Resp | [9,109] | |
c.325G"/>C | 35-45Skel | [114] | |
c.343delT* | 4 months Skel | [110] | |
c.358A"/>G | ?Skel | [98,99,115-122] | |
c.451C"/>T | 43Skel | [108,123,124] | |
c.460G"/>A | 48-68Skel or Card | [111,112] | |
c.464CTdel | 52 Resp | [108] | |
c.470G"/>A | 40'sCard | [113] |
4. Myotilin and myotilinopathies
The first description of myotilinopathy was a missense mutation in a family with LGMD1A [10]. Since this initial discovery, nine additional mutations in Myotilin (myofibrillar protein with Titin-like immunoglobulin domains) have been implicated in LGMD1A [10,140-142], MFM [143], SBM [144] or late onset distal myopathy [145] with all mutations described to date displaying an autosomal dominant pattern of inheritance. One of the mutations identified, S55F, has been found as a cause of both LGMD [141] and MFM [143] suggesting there may be modifiers of the disease that determine the symptoms produced or that there is an overlap in the classification of these conditions that needs to be resolved. Distinctions between these conditions are not clear, since the presence of protein aggregates is associated with MFM and SBM with weakness of distal muscle groups thought to be associated with MFM [143] and proximal muscle groups with LGMD (Table 4).
Myotilin belongs to the immunoglobulin domain containing Actin binding protein family that also contains the Actin organizing proteins Palladin and Myopalladin [146,147]. Myotilin is predominantly expressed in skeletal and cardiac muscle, with the highest levels present in the skeletal muscle. Expression is also detectable at low levels in the peripheral nerves, bone marrow, liver, thyroid gland and lung [153,154]. In skeletal muscle Myotilin is present in both slow type I and fast type II fibers [151] and is localised to the Z-disk [153], although some reports have suggested Myotilin may also be found at the sarcolemma [10,153,155]. A role at the sarcolemma is also supported by the inclusion of Dystrophin in the protein aggregates found in MFM and LGMD1A [10,143]. Like many other Z-disk proteins Myotilin is very dynamic as demonstrated by fluorescent recovery after photobleaching (FRAP) experiments in quail skeletal muscle that showed that 80% of Myotilin in the Z-disk is replaced within five minutes of bleaching [156].
Myotilin contains two identified domains, both essential for its function; a serine rich N-terminal domain, that shares no homology with any known protein, and a C-terminal domain consisting of two Ig-like domains that share high homology to two Z-disk associated Ig-like domains of the giant protein Titin [153] (Figure 3).Seven of the eight identified Myotilin mutations, including the three MFM mutations [143], are in the serine rich domain with one mutation in the second Ig domain [142]. The serine rich domain consists of a stretch of hydrophobic residues that are believed to direct the localisation of Myotilin to the sarcolemma [10]. The serine rich domain is also responsible for the interaction of Myotilin with a range of proteins including the primary Z-disk crosslinker -Actinin [153], Filamin- Actin- and Telethonin-binding protein of the Z-disk (FATZ, Myozenin, Calsarcin) [157], ZASP/Cypher [158], Filamin C [157,159] and the ubiquitin ligases MURF-1 and MURF-2 [160]. Interaction of Myotilin with FATZ directly or indirectly directs the localisation of FATZ to the Z-disk [157]. Myotilin also links Filamin C, found at the periphery of the Z-disk, to -Actinin and anchors the Actin containing thin filaments to the Z-disk thereby providing stability to the sarcomere
c.17G"/>A | 40Skel | [140] | |
c.116C"/>T | Childhood-60sSkel | [144] | |
c.164C"/>T | 48-53Skel | [141,143,148-150] | |
c.170C"/>T | 27Skel | [10,151] | |
c.179C"/>G | 50-77Skel | [143,148,152] | |
c.179C"/>T | 40-76Skel | [145] | |
c.284G"/>T | ? | [143] | |
c.1214G"/>A | 41Skel | [142] | |
c.1214G"/>A | 41Skel | [140] |
[159,161]. The Ig domain containing C-terminus on the other hand is responsible for antiparallel dimerization of Myotilin, which is essential for its function [153,161]. The Myotilin C-terminus alsointeracts directly with Actin, despite the lack of a conventional Actin binding site [162], and is thought to prevent the depolymerisation of Actin filaments and enhance the binding of -Actinin to Actin. Overexpression of Myotilin in CHO cells results in formation of Actin bundles and the delayed expression of Myotilin relative to other Z-disk proteins is thought to be required to avoid premature bundling of Actin fibres [161,162].
Despite the loss of muscle integrity in myotilinopathies Myotilin knockout mice display no muscle defects. Their Z-disk structure and sarcolemma integrity is maintained with no effect on muscle strength and the heart appears normal [163,164]. This suggests that other closely related proteins, such as Palladin and Myopalladin, may have overlapping functions to that of Myotilin and are able to compensate for its loss. Interestingly, mice deficient in Myotilin have a two fold increase in the expression of the muscle stretch sensor Telethonin, which may be responsible for sensing the lack of Myotilin and triggering appropriate signals to prevent muscle failure [163].However, this hypothesis needs to be validated.
Analysis of Myotilin levels in patients compared to control individuals failed to identify a reduction in protein level [10,142] with other studies reporting an increase in Myotilin in some patients [142,165]. This observation leads to the hypothesis that mutations in Myotilin affect its dimerisation or interaction with binding partners, resulting in pathology. This is certainly true in the case of the identified missense mutation affecting the second Ig domain of Myotilin (R405K) resulting in LGMD [142]. The R405K mutation prevents dimerisation disrupting α-Actinin binding and Actin tethering to the Z-disk. As a result, filament stability is lost, the Z-disk is destabilised, and protein aggregates are formed [142]. However, this is not true for the majority of Myotilin mutations, which are found in the serine rich N-terminal domain.
The formation of protein aggregates is a defining feature of MFM and SBM. Aggregate containing muscle from myotilinopathy patients contains increased levels of oxidative stress markers including glycation end products, nitric oxide synthase, superoxide dismutase, and mutant Ubiquitin [166,167]. Protein oxidation promotes protein aggregation and reduces proteolytic degradation. Another factor that may promote protein aggregation in myotilinopathies and other MFMs is the inability of cells to degrade misfolded proteins via the non-lysosomal ubiquitin proteasome system (UPS) responsible for the degradation of 80-90% of myofibrillar proteins [168]. UPS mediated degradation of mutant Myotilin is significantly slower than wildtype Myotilin and inhibition of Myotilin turnover results in aggregates similar to those seen in MFM[169].
5. ZASP and zaspopathies
Z band alternatively spliced PDZ-containing protein (ZASP)[170], also known as LIM Domain Binding 3 (LDB3), Cypher [171], or Oracle [172] belongs to the PDZ-LIM family of proteins and similar to other members of the family, Enigma [173] and α-Actinin associated LIM protein (ALP) [174], localises to the Z-disk. More than 15 mutations in ZASP have been reported resulting in a range of myopathies including DCM [11,175], HCM [176], MFM [177], inclusion body myositis [178], and LVNCC [11,175,177] (Table 5). ZASP contains a PDZ domain, located at the N-terminus, and an internal ZASP/cypher-like motif (ZM) both capable of interacting with α-Actinin-2 [179-181]. Additionally, the PDZ domain interacts with Myotilin [158] and FATZ[182], which provides structural stability to the Z-disk. The C-terminus contains three LIM domains, which act to recruit signalling proteins to the Z-disk.
As its name suggests the ZASP mRNA is extensively spliced to result in multiple ZASP isoforms, a feature conserved in all species examined with four isoforms in worms [183], 12 isoforms in flies [184-186], 13 in zebrafish [187], and six in mice and humans [11,188] (Figure 4). In mice and humans the isoforms have been characterised according to their length and their expression in the heart or skeletal muscle. So far two short isoforms, (2c, 2s) that lack the LIM domains, and four long isoforms (1c, 1s, 3c and 3s), that contain all three LIM domains, have been characterised [11,170]. Isoforms containing exon four (1s, 2s and 3s) are restricted to cardiac muscle whereas isoforms lacking exon four are found in both cardiac and skeletal muscle [11]. Loss and gain of function experiments have highlighted specific roles for the short and long isoforms. Selective deletion of the short isoforms does not lead to any muscle defects however, loss of the long isoforms results in neonatal lethality in 28% of mice [189]. Surviving knockout mice display growth retardation and Z-disk abnormalities in cardiomyocytes leading to DCM in adulthood, demonstrating the requirement for the
c.163G"/>A* | ?Card | [175,191] | |
c.349G"/>A | 30-41Card | [11] | |
c.407C"/>T | 16Card | [11] | |
c.464G"/>A (mRNA) | 44-59Skel | [177] | |
c.519C"/>T (mRNA) | 39-59Skel | [177,192] | |
c.587C"/>T | 7-73 (not accurate)Card | [11,176,193] | |
c.638C"/>T | 15 monthsCard | [11] | |
c.827C"/>T (mRNA) | 73Skel | [177] | |
c.1056C"/>G | <15-35Card | [11] | |
? | 68Card | [176] | |
? | 46Card | [176,191] | |
? | 21Card | [176,191] | |
c.1719G"/>A | 40Skel | [178] | |
? | 28Card | [176] | |
c.1876G"/>A | after birth-69Card | [175,191] |
long, but not the short, isoforms in maintaining Z-disk integrity [189]. Loss of both short and long isoforms however, results in death within the first five days [190] suggesting that there is some redundancy in their roles. This hypothesis is supported by rescue experiments showing that expression of either the short or long skeletal isoform in ZASP deficient mice is sufficient for survival in 19% and 49% of carriers respectively [188]. The different phenotypes observed following loss of long or short isoforms raises the question whether mutations in specific isoforms result in specific myopathies. This is clearly true in the case of mutations in the cardiac specific exon four however, why mutations in exons expressed in both skeletal and cardiac muscle results in only one tissue getting affected is not clear. For example the D117N [11], A147W, and A165V [177] mutations in exon six affect both skeletal and cardiac muscle isoforms. However, D117N preferentially affects the cardiomyocytes whereas A165V preferentially affects the skeletal muscle, and A147W results in both tissues being affected. Therefore, there appears to be no clear correlation between the exon affected and the phenotype presented by the patient.
Examination of the diaphragm muscles, which are not active before birth, in ZASP knockout mice identified little or no difference in the sarcomere structure at E17.5 when compared with wildtype mice, but severe disruption of the Z-disk the day after birth [190], suggesting that ZASP is not required for sarcomere assembly but is critical for maintenance of Z-disk integrity. Examination of cardiac muscle in these mice, which becomes active at E8, at E17.5 identified severely disrupted Z-disks which were completely lost by one day after birth [190]. A role for ZASP in Z-disk maintenance is supported by experiments demonstrating that deletion of ZASP in postnatal hearts results in gradual disruption of the Z-disk and severe DCM resulting in premature death within five months [194]. Targeted deletion of ZASP homologues in
In cardiomyocytes ZASP interacts with Protein Kinase C (PKC) [175], a known modulator of cardiomyocyte growth and contractility. PKC-ε has been shown to interact with RACK-2 and protect cardiomyocytes from ischemic stress [195,196]. Disruption of the PKC-ε - RACK-2 complex results in inhibition of cell contraction [197] and accelerated cell death [198].
6. Filamin and filaminopathies
Filamin C (FLNC) was first implicated in MFM in 2005 with the identification of a missense mutation in a German family that presented with weakness of the proximal muscle groups and respiratory insufficiency [12]. Since this initial discovery five additional FLNC mutations have been identified of which two result in MFM [203,204] and three cause distal myopathies in which protein aggregates are not evident [205,206] (Table 6).
c.577G"/>A | 30'sSkel | [205] | |
c.752T"/>C | 30'sSkel | [205] | |
c.2695_2712del + GTTTGTins | 35-40Skel | [204] | |
c.2788_2799del | 34-60Skel | [203] | |
c.5160delC | 20-57Skel | [206] | |
c.8130G"/>A | 24-49Skel | [4,12,207] |
FLNC belongs to the Filamin family of proteins characterised by their ability to cross link Actin. Three Filamin isoforms have been identified all of which are encoded by different genes [208,209]: Filamin A (α-Filamin or Filamin 1) and Filamin B (β-Filamin), which are ubiquitously expressed, and FLNC (Filamin 2, γ-Filamin, Actin Binding Protein 280 (ABP-280) or Actin Binding Protein Ligand (ABP-L)) [210-212], which is expressed specifically in striated and cardiac muscle [204,212]. In striated muscle, FLNC localises in two different pools: 97% of FLNC is contained within the Z-disk of the sarcomere and 3% is found in the sarcolemmal membrane at the level of the costameres and myotendinous junctions [213]. In cardiac muscle FLNC is found in intercalated discs [213,214].
Filamin proteins contain two distinct functional regions (Figure 5). The N-terminal region, which contains two calpain homology domains that are responsible for interacting with Actin and promoting its polymerisation [215]. Two of the three distal myopathy causing FLNC mutations, in which protein aggregates are not evident, are found in this N-terminal region. This suggests that the presence of a functional N-terminal Actin binding domain in MFM causing FLNC mutant protein may be important in the formation of protein aggregates. The other four FLNC mutations are found in the semi-flexible rod domain, which contains 24 homologous Ig-like domains, each about 93 to 103 amino acids long [203]. The Ig-like domains act as an interface for the interaction of FLNC with its binding partners and allow FLNC dimerisation, through domain 24 [216], which is essential for its function.
Disruption of FLNC dimerisation leads to failure of the Z-disk as in the case of W2710X MFM causing FLNC mutation. Truncation of the dimerisation domain results in the loss of secondary structure of the mutant protein hence making it less stable and more susceptible to degradation by proteolytic enzymes [12,207], but is also more prone to aggregation [207]. Although the mutant protein is unable to form dimers, it neither disturbs dimerisation of wildtype FLNC nor affects its interaction with Actin or the sarcoglycans, two key FLNC binding partners [207]. In between FLNC Ig-like domains 15 and 16 (Figure 5), a differentially spliced Hinge 1 (H1) region is present, that provides flexibility to FLNC, but is absent from the predominant form expressed in striated muscle. Additionally, FLNC has a second hinge region (H2, Figure 5) between Ig-like domains 23 and 24, found in both splice variants [210,212], and contains a unique 82 amino acid insert between Ig-like domains 19 and 20 [213], which is thought to recruit FLNC specifically into the Z-disk [157].
FLNC has been proposed to have several functions in the muscle. The interaction of Ig-like domain 20 of FLNC with the Z-disk protein Xin is important in regulating the development and remodelling of the Actin cytoskeleton [217]. Additionally, the interaction of FLNC Ig-like domains 19, 20,21, and domain 23 with the Z-disk proteins Myotilin [159] and FATZ [157,182,218,219] maintains the stability of the sarcomere. At the sarcolemma, FLNC interacts with the transmembrane proteins γ- and δ-Sarcoglycans (repeats 20 to 24) [213], Cbl-associated protein (CAP or Ponsin, domain 2) [220], Ankyrin G (repeat 5 and 6) [221], and β1-integrin (domain 20-21) [157]. FLNC therefore connects the Z-disk to the sarcolemma and the ECM providing both a structural linkage and a mechanism for signalling from the sarcolemma to the Z-disk [159,213]. In cardiac muscle FLNC interacts with Nebulette [222], the cardiac specific homologue of the thin filament ruler Nebulin. This interaction has been thought to be important in targeting FLNC to the cytoskeleton therefore ensuring the correct localisation and function of FLNC. FLNC, through Ig-like domains 20, 21, and 23 also interacts with the muscular dystrophy KY protein but the functional importance of this interaction is not known [214]. The identification of a distal myopathy as a result of FLNC haploinsufficiency suggests that the levels of FLNC maybe critical for its function [206]. Additionally, the altered distribution of both sarcomeric and ECM proteins in filaminopathies suggests that the functions of FLNC at the Z-disk and sarcolemma are compromised in filaminopathies. Analysis of the FLNC mouse knockout identified a decrease in the number of primary muscle fibres suggesting a role for FLNC in myogenesis [223]. However, the recent characterisation of a Medaka FLNC mutant showed no difference in the expression of myogenic factors [224]. The role of FLNC in fibre differentiation is therefore still questionable.
The process by which mutations in FLNC result in muscle disease is not understood but the identification of a haploinsufficient form of filaminopathy, and the finding that the W2710X mutant does not disrupt wildtype FLNC dimerisation,together with the severe muscle defects seen in the FLNC knockout mouse suggest that Filamin related MFM manifests as result of direct or indirect loss of functional FLNC. It is therefore hypothesised that the progressive, late-onset, nature of filaminopathies results from a reduction in FLNC function commensurate with the increasing sequestration of wildtype FLNC and FLNC binding partners by mutant FLNC in the cytoplasm.
6. BAG3 and bag3opathies
Bcl2-related athanogene 3 (BAG3, Bis, CAIR) is the most recently identified MFM causing Z-disk protein with the report of a missense mutation (P209L) in exon three resulting in MFM with cardiac complications [13]. Since then 10 additional
c.211C"/>T | 41-59Card | [225] | |
c.268C"/>T | 44Card | [225] | |
c.326A"/>G | 21Card | [225] | |
c.367C"/>T | 25-36Card | [225] | |
c.626C"/>T | 5-13Skel and Card | [13,226,228,240] | |
c.625C"/>T + c.772C"/>T | 6Skel | [227] | |
c.652C"/>T | 73Card | [226] | |
c.652Cdel | 47Card | [225] | |
c.784G"/>A | 42-44Card | [225] | |
c.1385T"/>C | 27-34Card | [226] | |
c.1430G"/>A | 47-50Card | [225] |
BAG3 has three recognisable functional domains (Figure 6); no mutations have been reported in the WW domain containing N-terminal region, which interacts with proline rich motifs of signal transduction proteins, or in the proline rich central region, which interacts with WW domains and Src3 homology (SH3) domains of signal transduction proteins such as Phospholipase C (PLCγ) [233].
Two mutations have however been reported in the evolutionary conserved C-terminal BAG domain that has a key role in the apoptotic and chaperone functions of BAG3 [234-236]. The BAG domain binds with high affinity to, and regulates, stress inducible Heat shock protein 70 (Hsp70) [233-235,237] and the constitutively expressed Heatshock cognate protein 70 (Hsc70) [237], that ensure
correct protein folding and targeting of misfolded proteins for proteasomal degradation [238]. BAG3 competitively binds to the ATPase domain of these chaperone proteins and alters their chaperone properties thereby targeting chaperone associated proteins for proteasomal degradation [237,239]. In fact, BAG3 has recently been shown to form a stable complex with the small Heat shock protein HspB8 and stimulate macroautophagy [236], a process that is particularly important in Huntington disease where association of BAG3 with HspB8 promotes degradation of mutant Huntingtin [236,241]. In inclusion body myositis, macroautophagy plays a role in removing β-amyloid aggregates [242] and it is possible that BAG3 also plays a role in this cellular response to protein aggregates in MFM. However, as the primary defect in MFM is the dissolution of muscle fibres beginning at the Z-disk preventing the formation of protein aggregates is unlikely to be sufficient to prevent muscle pathology.
In B-crystallinopathies BAG3 suppresses protein aggregation and toxicity by preferentially binding mutant CRYAB, reducing its aggregation and increasing its solubility [136]. This demonstrates that BAG3 not only indirectly regulates protein folding and degradation but also has the potential to prevent misfolding and promote degradation of mutant proteins thereby preventing disease pathology. Interestingly, deletion of the BAG domain results in a similar inhibition of aggregation of mutant CRYAB. BAG3 may therefore function through a pathway that is independent of Hsp70/Hsc70 [136]. BAG3 synergisticallyinteracts with Bcl-2, via the BAG domain, to prevent Bax induced and FasL-
Fas mediated apoptosis [239,243]. BAG3 levels are up-regulated in response to oxidative stress [244], heat shock, heavy metal exposure [245,246], or photoinjury in the retina [247] and increased levels of BAG3 in human epithelial cells has been show to result in decreased Bax or Fas mediated apoptosis demonstrating the critical adaptive role of BAG3 in response to cell stress.
Immunohistochemistry on P209L mutant muscle biopsy samples revealed increased immunoreactivity in abnormal fibres for the chaperone molecules Hsp27 and CRYAB and the anti- apoptotic protein Bcl-2. This was accompanied by increased apoptosis suggesting that the P209L mutation interfered with the anti-apoptotic functions of BAG3 [13]. Non-denaturing gel electrophoresis revealed faster migration of the mutant BAG3 complex than wildtype [13], suggesting that the loss of function may be due to reduced interaction with partner proteins, possibly Bcl-2, given that an increase in apoptosis is observed. This is supported by transfection of P209L mutant BAG3 into neonatal cardiomyocytes resulting in increased susceptibility to stress mediated apoptosis [226] and the observation that mice deficient in BAG3 also display increased apoptosis [228]. It has been shown that the down-regulation of BAG3 enhances the apoptotic response to chemotherapy in lymphocytic leukaemia cells making it a potential target for cancer therapies [248], and further demonstrating its anti-apoptotic role.
Since the primary defect in BAG3opathies is the fragmentation of fibres it can be postulated that perhaps BAG3 has a role in muscle development or maintenance of muscle structure. BAG3 deficient mice are normal at birth but cease to gain weight at day 12. Muscle histology revealed myofibril and Z-disk defects with no sarcolemma damage [228]. Taken together, this data suggests that BAG3 is not necessary for sarcomerogenesis but is critical for maintenance of fibre integrity. By the 25th day BAG3 deficient mice die as a result of intercostal muscle failure or pulmonary oedema that results in cardiac failure [228]. Targeted knockdown of BAG3 in zebrafish has also resulted in severe cardiac defects demonstrating a critical role of BAG3 in maintaining the structural integrity of cardiomyocytes [225]. A recent study has shown that BAG3 regulates myofibril stability by facilitating the interaction of Hsc70 with CapZ, a protein that caps the barbed ends of Actin filaments that extend into Z-disk [230]. Loss of BAG3 makes CapZ more vulnerable to degradation resulting in loss of CapZ and fibre fragmentation following mechanical stress [230].
In summary, the most recently identified MFM causing gene plays key roles in the localisation of CapZ to the Z-disk through its interaction with Hsc70, protein folding and degradation, and in the regulation of apoptosis. Given the indirect role BAG3 plays in Z-disk and muscle function, its binding partners are excellent candidates for further genes that may be mutated in MFM. However, given the fact that most of the identified disease causing mutations lie outside a recognised domain in BAG3 there may be many more functions for BAG3 that remain to be characterised, perhaps including a direct role in the Z-disk.
7. Conclusion
The many functions of the MFM proteins, which are themselves just a very small subset of the Z-disk associated proteins, highlights the complex and dynamic nature of the Z-disk. Whilst a characteristic feature of MFM is dissolution of the myofibril, originating at the Z-disk, these disorders are not due to simple loss or disruption of structural components in this tensile load bearing structure. This is exemplified by the identification of BAG3, which localises to the Z-disk but appears to only have indirect association to it, as an MFM protein. Further support comes from analysis of mouse knockouts for the MFM genes, none of which have defects in the formation of myofibrils.
The progressive nature of the disease and the identification of roles for the associated proteins in muscle repair and maintenance is more suggestive of a gradual accumulation of defects in Z-disk organisation eventually leading to structural failure. An interesting finding from mice lacking the long isoforms of ZASP is that they have increased levels of the MFM proteins Myotilin, CRYAB, and FLNC as well as the extracellular matrix proteins β1D Integrin and the sarcoglycans [189]. Up-regulation of Z-disk components is observed in α-Actinin-3 knockout mice in which FLNC, Myotilin, ZASP, and CRYAB are up-regulated [249]. Increased levels of FLNC are also detected in patients with LGMD or Duchenne muscular dystrophy [213]. This data, together with that previously presented, strongly supports the idea that the MFM proteins are up-regulated to protect the sarcomere and ECM from damage, whether that damage is caused by muscle activity, mutation of muscle proteins, or increases in oxidative, metabolic, and other forms of cell stress. Whether this is through a general stress response pathway that up-regulates the expression of Z-disk associated proteins or through a more specific pathway that selectively target proteins based on the nature of the stress remains to be determined.
For more than half of the cases of MFM the causative mutation is not known. As we have described there are many binding partners for the known MFM proteins, mutations in which may account for some of these cases. Additionally there is evidence from experiments with Desmin that mutations in other genes may act as modifiers of disease. Far more mutations have been identified in Desmin than in other MFM genes and it may be that modifiers will be identified in other subtypes of MFM as larger cohorts are analysed. Given the hypothesised role for the MFM proteins in stress response it is possible that any mutations that result in cellular stress may modify the presentation of MFM perhaps accounting for some of the differences in age of onset. Furthermore, differences in stress between cardiac and skeletal tissues may explain the differences in symptoms between these tissues, even in individuals with the same mutation. As the application of whole genome sequencing to mutation detection in myopathy becomes more widespread it may be possible to identify potential modifiers and investigate their role in MFM.
The existing literature on MFM and the MFM associated proteins has identified many exciting avenues for investigation. To investigate these areas further animal models, modelling specific MFM mutations, are required that would allow for better characterisation of pathology and the progression of disease together with a consistent genetic background to allow the analysis of potential genetic modifiers. The development of better tools to investigate the function of the MFM proteins, together with the identification of further MFM genes and modifiers, will allow us to improve our understanding of the many diverse and complex roles of these Z-disk associated proteins and move closer to the development of effective therapies for these conditions.
8. Abbreviations
ACD domain: -crystallin domain AVB: atrioventricular block BAG3: Bcl2-related athanogene 3 CM: cardiomyopathy CRYAA: αA-Crystallin CRYAB: αB-Crystallin DCM: dilated cardiomyopathy DRM: Desmin-related myopathy ECM: extracellular matrix FLNC: Filamin C HCM: hypertrophic cardiomyopathy IF: intermediate filament Ig: immunoglobulin LVNCC: left ventricular non-compaction cardiomyopathy MA: muscle atrophy MFM: myofibrillar myopathy MW: muscle weakness PGM1: Phosphoglucomutase 1 PKC: Protein kinase C SBM: spheroid body myopathy ULF: unit length filament UPS: ubiquitin proteasome system UTR: untranslated region VEFR: ventricular ejection fraction reduction ZASP: Z-band alternatively spliced PDZ-motif protein WT: wildtype ZM: ZASP/Cypher-like motif GFAP: Glial fibrillary acidic protein |
Acknowledgement
The authors would like to thank Dr Jihane Homman-Ludiye for her comments on the manuscript.
References
- 1.
Myofibrillar myopathy with abnormal foci of desmin positivity. I. Light and electron microscopy analysis of 10 cases. J. Neuropathol. Exp. Neurol.Nakano S. Engel A. G. Waclawik A. J. Emslie-Smith A. M. Busis N. A. 1996 55 549 62 - 2.
Clinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy. Neuromuscul DisordOlivé M. Odgerel Z. Martínez A. Poza J. J. Bragado F. G. Zabalza R. J. Jericó I. Gonzalez-Mera L. Shatunov A. Lee-S H. Armstrong J. Maraví E. Arroyo M. R. Pascual-Calvet J. Navarro C. Paradas C. Huerta M. Marquez F. Rivas E. G. Pou A. Ferrer I. Goldfarb L. G. 2011 - 3.
Differential involvement of sarcomeric proteins in myofibrillar myopathies: a morphological and immunohistochemical study. Acta Neuropathol.Claeys K. G. Ven P. F. M. Behin A. Stojkovic T. Eymard B. Dubourg O. Laforêt P. Faulkner G. Richard P. Vicart P. Romero N. B. Stoltenburg G. Udd B. Fardeau M. Voit T. DO Fürst 2009 117 293 307 - 4.
Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patients. BrainKley R. A. Hellenbroich Y. van der Ven P. F. M. DO Furst Huebner. A. Bruchertseifer V. Peters S. A. Heyer C. M. Kirschner J. Schroder R. Fischer D. Muller K. Tolksdorf K. Eger K. Germing A. Brodherr T. Reum C. Walter M. C. Lochmuller H. Ketelsen U. P. Vorgerd M. 2007 130 3250 64 - 5.
Brain PathologySchröder R. Schoser B. Myofibrillar Myopathies. A. Clinical Myopathological Guide. 2009 19 483 92 - 6.
Molecular pathology of myofibrillar myopathies. Expert Reviews in Molecular MedicineFerrer I. Olivé M. 2008 - 7.
DisordSelcen D. Myofibrillar myopathies. Neuromuscul 2011 21 161 71 - 8.
Autosomal dominant distal myopathy with desmin storage: a clinicopathologic and electrophysiologic study of a large kinship. Muscle NerveHorowitz S. H. Schmalbruch H. 1994 17 151 60 - 9.
Canadian Natives. Can J Neurol SciLacson A. G. Seshia S. S. Sarnat H. B. Anderson J. De Groot W. R. Chudley A. Adams C. Darwish H. Z. Lowry R. B. Kuhn S. Autosomal recessive. fatal infantile. hypertonic muscular. dystrophy among. Canadian Natives. 1994 21 203 12 - 10.
Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum. Mol. Genet.Hauser M. Horrigan S. Salmikangas P. Torian U. Viles K. Dancel R. Tim R. Taivainen A. Bartoloni L. Gilchrist J. Stajich J. Gaskell P. Gilbert J. Vance J. Pericak-Vance M. Carpén O. Westbrook C. Speer M. 2000 9 2141 7 - 11.
J. Am. Coll. Cardiol.Vatta M. Mohapatra B. Jimenez S. Sanchez X. Faulkner G. Perles Z. Sinagra G. Lin J. H. Vu T. M. Zhou Q. Bowles K. R. Di Lenarda A. Schimmenti L. Fox M. MA Chrisco Murphy. R. T. Mc Kenna W. Elliott P. Bowles N. E. Chen J. Valle G. Towbin J. A. Mutations in. Cypher Z. A. S. P. in patients. with dilated. cardiomyopathy left ventricular. non-compaction 2003 42 2014 27 - 12.
A, Schröder R, Lochmüller H, Himmel M, Koehler K, Fürst DO, Huebner A. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am. J. Hum. Genet.Vorgerd M. van der Ven P. F. M. Bruchertseifer V. Löwe T. Kley R. A. Schröder R. Lochmüller H. Himmel M. Koehler K. DO Fürst Huebner. A. 2005 77 297 304 - 13.
Ann. Neurol.Selcen D. Muntoni F. Burton B. K. Pegoraro E. Sewry C. Bite A. V. Engel A. G. Mutation in. B. A. G. causes severe. dominant childhood. muscular dystrophy. 2009 65 83 9 - 14.
GeneReviews;Selcen D. Engel A. G. Myofibrillar Myopathy. Seattle Gene. 2005 - 15.
Electron microscopy in myofibrillar myopathies reveals clues to the mutated gene. Neuromuscul DisordClaeys K. G. Fardeau M. Schroder R. Suominen T. Tolksdorf K. Behin A. Dubourg O. Eymard B. Maisonobe T. Stojkovic T. Faulkner G. Richard P. Vicart P. Udd B. Voit T. Stoltenburg G. 2008 18 656 66 - 16.
Immunological characterization of the subunit of the 100 A filaments from muscle cells. Proc. Natl. Acad. Sci. U.S.A.Lazarides E. BD Hubbard 1976 73 4344 8 - 17.
Price MG. Molecular analysis of intermediate filament cytoskeleton--a putative load-bearing structure. Am. J. Physiol.1984 H566 72 - 18.
Association of plectin with Z-discs is a prerequisite for the formation of the intermyofibrillar desmin cytoskeleton. Lab InvestSchroder R. DO Furst Klasen. C. Reimann J. Herrmann H. van der Ven P. F. 2000 80 455 64 - 19.
Alpha B-crystallin in cardiac tissue. Association with actin and desmin filaments. Circ. Res.Bennardini F. Wrzosek A. Chiesi M. 1992 71 288 94 - 20.
Molecular dissection of the interaction of desmin with the C-terminal region of nebulin. J. Struct. Biol.Bang-L M. Gregorio C. Labeit S. 2002 137 119 27 - 21.
Conover GM, Gregorio CC. The desmin coil 1B mutation K190A impairs nebulin Z-disc assembly and destabilizes actin thin filaments. J Cell Sci2011 124 3464 76 - 22.
Bellin RM, Huiatt TW, Critchley DR, Robson RM. Synemin may function to directly link muscle cell intermediate filaments to both myofibrillar Z-lines and costameres. J Biol Chem2001 276 32330 7 - 23.
Isolation of a new high molecular weight protein associated with desmin and vimentin filaments from avian embryonic skeletal muscle. J. Cell Biol.Breckler J. Lazarides E. 1982 92 795 806 - 24.
Proc. Natl. Acad. Sci. U.S.A.Mizuno Y. Thompson T. G. Guyon J. R. Lidov H. G. Brosius M. Imamura M. Ozawa E. Watkins S. C. Kunkel L. M. Desmuslin an. intermediate filament. protein that. interacts with. alpha-dystrobrevin desmin 2001 98 6156 61 - 25.
Direct involvement of a lamin-B-related (54 kDa) protein in the association of intermediate filaments with the postsynaptic membrane of the Torpedo marmorata electrocyte. J Cell SciCartaud A. Jasmin B. J. Changeux J. P. Cartaud J. 1995 Pt 1):153-60. - 26.
Plectin interacts with the rod domain of type III intermediate filament proteins desmin and vimentin. Eur. J. Cell Biol.Favre B. Schneider Y. Lingasamy P. Bouameur-E J. Begré N. Gontier Y. Steiner-Champliaud-F M. MA Frias Borradori. L. Fontao L. 2011 90 390 400 - 27.
Limited co-assembly in vitro to form heteropolymers with type III vimentin and type IV alpha-internexin. J Biol ChemSteinert P. M. Chou Y. H. Prahlad V. Parry D. A. Marekov L. N. Wu K. C. Jang S. I. Goldman R. D. A. high molecular. weight intermediate. filament-associated protein. in B. H. K- cells is. nestin a. type V. I. intermediate filament. protein 1999 274 9881 90 - 28.
Langley RC, Cohen CM. Association of spectrin with desmin intermediate filaments. J. Cell. Biochem.1986 30 101 9 - 29.
Binding of two desmin derivatives to the plasma membrane and the nuclear envelope of avian erythrocytes: evidence for a conserved site-specificity in intermediate filament-membrane interactions. Proc. Natl. Acad. Sci. U.S.A.Georgatos S. D. Weber K. Geisler N. Blobel G. 1987 84 6780 4 - 30.
Null mutation in the desmin gene gives rise to a cardiomyopathy. J. Mol. Cell. Cardiol.Thornell L. Carlsson L. Li Z. Mericskay M. Paulin D. 1997 29 2107 24 - 31.
Intermediate filaments and their associates: multi-talented structural elements specifying cytoarchitecture and cytodynamics. Curr. Opin. Cell Biol.Herrmann H. Aebi U. 2000 12 79 90 - 32.
Ann. N. Y. Acad. Sci.Weber K. Geisler N. Intermediate filaments. structural conservation. divergence 1985 455 126 43 - 33.
Biochem.Fuchs E. Weber K. Intermediate filaments. structure dynamics. function disease Annu. Rev 1994 63 345 82 - 34.
Heptad breaks in alpha-helical coiled coils: stutters and stammers. ProteinsBrown J. H. Cohen C. Parry D. A. 1996 26 134 45 - 35.
Biol.Goldfarb L. G. Olivé M. Vicart P. Goebel H. H. Intermediate filament. diseases desminopathy. Adv Exp. Med 2008 642 131 64 - 36.
BrainSelcen D. Myofibrillar myopathy. clinical morphological. genetic studies. in . patients 2004 127 439 51 - 37.
Disease mutations in the “head” domain of the extra-sarcomeric protein desmin distinctly alter its assembly and network-forming properties. J. Mol. Med.Sharma S. Mücke N. Katus H. A. Herrmann H. Bär H. 2009 87 1207 19 - 38.
High cardiovascular morbidity and mortality in myofibrillar myopathies due to DES gene mutations: a 10-year longitudinal study. Neuromuscul DisordWahbi K. Behin A. Charron P. Dunand M. Richard P. Meune C. Vicart P. Laforêt P. Stojkovic T. Bécane H. M. Kuntzer T. Duboc D. 2012 22 211 8 - 39.
Conspicuous involvement of desmin tail mutations in diverse cardiac and skeletal myopathies. Hum. Mutat.Bär H. Goudeau B. Wälde S. Casteras-Simon M. Mücke N. Shatunov A. Goldberg Y. P. Clarke C. Holton J. L. Eymard B. Katus H. A. Fardeau M. Goldfarb L. Vicart P. Herrmann H. 2007 28 374 86 - 40.
Mutations in desmin’s carboxy-terminal’tail’ domain severely modify filament and network mechanics. J. Mol. Biol.Bär H. Schopferer M. Sharma S. Hochstein B. Mücke N. Herrmann H. Willenbacher N. 2010 397 1188 98 - 41.
Two related Dutch families with a clinically variable presentation of cardioskeletal myopathy caused by a novel S13F mutation in the desmin gene. European Journal of Medical GeneticsBergman J. E. H. Veenstra-Knol H. E. van Essen A. J. van Ravenswaaij C. M. A. Dunnen den. W. F. A. van den Wijngaard. A. Peter van Tintelen. J. 2007 50 355 66 - 42.
Characterization of a novel S13F desmin mutation associated with desmin myopathy and heart block in a Chinese family. Neuromuscul DisordPica E. C. Kathirvel P. Pramono Z. A. D. Lai-S P. Yee-C W. 2008 18 178 82 - 43.
Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutationsSpaendonck-Zwarts K. Y. Kooi A. J. Berg M. P. Ippel E. F. Boven L. G. Yee W. C. Wijngaard A. Brusse E. Hoogendijk J. E. Doevendans P. A. Visser M. Jongbloed J. D. H. Tintelen J. P. S13F and p.N342D. Neth Heart J2011 - 44.
Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects. European Journal of Heart FailureArbustini E. Pasotti M. Pilotto A. Pellegrini C. Grasso M. Previtali S. Repetto A. Bellini O. Azan G. Scaffino M. 2006 8 477 83 - 45.
Prevalence of Desmin Mutations in Dilated Cardiomyopathy. CirculationTaylor M. R. G. Slavov D. Ku L. Di Lenarda A. Sinagra G. Carniel E. Haubold K. MM Boucek Ferguson. D. Graw S. L. Zhu X. Cavanaugh J. Sucharov C. C. Long C. S. Bristow M. R. Lavori P. Mestroni L. for the. Familial Cardiomyopathy. Registry the B. E. S. T. . Beta-Blocker Evaluation. of Survival. Trial D. N. A. Bank 2007 - 46.
Myocardial fibrosis in desmin-related hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic ResonanceHe Y. Zhang Z. Hong D. Dai Q. Jiang T. 2010 - 47.
Hum. Pathol.Ariza A. Coll J. Fernández-Figueras M. T. MD López Mate. J. L. García O. Fernández-Vasalo A. Navas-Palacios J. J. Desmin myopathy. a. multisystem disorder. involving skeletal. cardiac smooth muscle. 1995 26 1032 7 - 48.
Proc. Natl. Acad. Sci. U.S.A.Muñoz-Mármol A. M. Strasser G. Isamat M. Coulombe P. A. Yang Y. Roca X. Vela E. Mate J. L. Coll J. Fernández-Figueras M. T. Navas-Palacios J. J. Ariza A. Fuchs E. A. dysfunctional desmin. mutation in. a. patient with. severe generalized. myopathy 1998 95 11312 7 - 49.
Severe muscle disease-causing desmin mutations interfere with in vitro filament assembly at distinct stages. Proc. Natl. Acad. Sci. U.S.A.Bär H. Mücke N. Kostareva A. Sjöberg G. Aebi U. Herrmann H. 2005 102 15099 104 - 50.
Variable pathogenic potentials of mutations located in the desmin alpha-helical domain. Hum. Mutat.Goudeau B. Rodrigues-Lima F. Fischer D. Casteras-Simon M. Sambuughin N. de Visser M. Laforêt P. Ferrer X. Chapon F. Sjöberg G. Kostareva A. Sejersen T. Dalakas M. C. Goldfarb L. G. Vicart P. 2006 27 906 13 - 51.
Desmin splice variants causing cardiac and skeletal myopathy. J. Med. Genet.Park K. Y. Dalakas M. C. Goebel H. H. Ferrans V. J. Semino-Mora C. Litvak S. Takeda K. Goldfarb L. G. 2000 37 851 7 - 52.
N. Engl. J. Med.Dalakas M. C. Park K. Y. Semino-Mora C. Lee H. S. Sivakumar K. Goldfarb L. G. Desmin myopathy. a. skeletal myopathy. with cardiomyopathy. caused by. mutations in. the desmin. gene 2000 342 770 80 - 53.
How much mutant protein is needed to cause a protein aggregate myopathy in vivo? Lessons from an exceptional desminopathy. Hum. Mutat.Clemen C. S. Fischer D. Reimann J. Eichinger L. M. ller C. R. M. ller H. D. Goebel H. H. Schr der R. 2009 E490 9 - 54.
On noxious desmin: functional effects of a novel heterozygous desmin insertion mutation on the extrasarcomeric desmin cytoskeleton and mitochondria. Hum. Mol. Genet.Schroder R. Goudeau B. Simon M. Fischer D. Eggermann T. Clemen C. Li Z. Reimann J. Xue Z. Rudnik-Schoneborn S. Zerres K. van der Ven P. Furst D. Kunz W. Vicart P. 2003 12 657 69 - 55.
The enlarging spectrum of desminopathies: new morphological findings, eastward geographic spread, novel exon 3 desmin mutation. Acta Neuropathol.Vrabie A. Goldfarb L. G. Shatunov A. Nägele A. Fritz P. Kaczmarek I. Goebel H. H. 2005 109 411 7 - 56.
Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat. Genet.Goldfarb L. G. Park K. Y. Cervenáková L. Gorokhova S. Lee H. S. Vasconcelos O. Nagle J. W. Semino-Mora C. Sivakumar K. Dalakas M. C. 1998 19 402 3 - 57.
Autopsy case of desminopathy involving skeletal and cardiac muscle. Pathol IntYuri T. Miki K. Tsukamoto R. Shinde A. Kusaka H. Tsubura A. 2007 57 32 6 - 58.
Hum. Mol. Genet.Sjöberg G. CA Saavedra-Matiz Rosen. D. R. Wijsman E. M. Borg K. Horowitz S. H. Sejersen T. A. missense mutation. in the. desmin rod. domain is. associated with. autosomal dominant. distal myopathy. exerts a. dominant negative. effect on. filament formation. 1999 8 2191 8 - 59.
Cytoskeletal derangements in hereditary myopathy with a desmin L345P mutation. Acta Neuropathol.Carlsson L. Fischer C. Sjöberg G. Robson R. M. Sejersen T. Thornell-E L. 2002 104 493 504 - 60.
Pathogenic effects of a novel heterozygous R350P desmin mutation on the assembly of desmin intermediate filaments in vivo and in vitro. Hum. Mol. Genet.Bär H. Fischer D. Goudeau B. Kley R. A. Clemen C. S. Vicart P. Herrmann H. Vorgerd M. Schröder R. 2005 14 1251 60 - 61.
Neuromuscul DisordFidzianska A. Kotowicz J. Sadowska M. Goudeau B. Walczak E. Vicart P. Hausmanowa-Petrusewicz I. A. novel desmin. R3 mutation P. causes cardiac. skeletal myopathy. 2005 15 525 31 - 62.
Respiratory insufficiency in desminopathy patients caused by introduction of proline residues in desmin c-terminal alpha-helical segment. Muscle NerveDagvadorj A. Goudeau B. Hilton-Jones D. Blancato J. K. Shatunov A. Simon-Casteras M. Squier W. Nagle J. W. Goldfarb L. G. Vicart P. 2003 27 669 75 - 63.
Small deletions disturb desmin architecture leading to breakdown of muscle cells and development of skeletal or cardioskeletal myopathy. Hum. Genet.Kaminska A. Strelkov S. V. Goudeau B. Olivé M. Dagvadorj A. Fidzianska A. Simon-Casteras M. Shatunov A. Dalakas M. C. Ferrer I. Kwiecinski H. Vicart P. Goldfarb L. G. 2004 114 306 13 - 64.
J. Neurol. Sci.Olivé M. Goldfarb L. Moreno D. Laforet E. Dagvadorj A. Sambuughin N. Martínez-Matos J. A. Martínez F. Alió J. Farrero E. Vicart P. Ferrer I. Desmin-related myopathy. clinical electrophysiological. radiological neuropathological. genetic studies. 2004 219 125 37 - 65.
Phenotypic patterns of desminopathy associated with three novel mutations in the desmin gene. Neuromuscul DisordOlivé M. Armstrong J. Miralles F. Pou A. Fardeau M. Gonzalez L. Martínez F. Fischer D. Martínez-Matos J. A. Shatunov A. Goldfarb L. Ferrer I. 2007 17 443 50 - 66.
Distinct phenotypic features and gender-specific disease manifestations in a Spanish family with desmin L370P mutation. Neuromuscul DisordArias M. Pardo J. Blanco-Arias P. Sobrido-J M. Arias S. Dapena D. Carracedo Á. Goldfarb L. G. Navarro C. 2006 16 498 503 - 67.
Neuromuscul DisordStrach K. Sommer T. Grohé C. Meyer C. Fischer D. Walter M. C. Vorgerd M. Reilich P. Bär H. Reimann J. Reuner U. Germing A. Goebel H. H. Lochmüller H. Wintersperger B. Schröder R. Clinical genetic. cardiac magnetic. resonance imaging. findings in. primary desminopathies. 2008 18 475 82 - 68.
NeurologySugawara M. Kato K. Komatsu M. Wada C. Kawamura K. Shindo S. Yoshioka N. Tanaka K. Watanabe S. Toyoshima I. A. novel de novo. mutation in. the desmin. gene causes. desmin myopathy. with toxic. aggregates 2000 55 986 90 - 69.
Structural and functional analysis of a new desmin variant causing desmin-related myopathy. Hum. Mutat.Goudeau B. Dagvadorj A. Rodrigues-Lima F. Nédellec P. Casteras-Simon M. Perret E. Langlois S. Goldfarb L. Vicart P. 2001 18 388 96 - 70.
J. Neurol.Dagvadorj A. Oliv M. Urtizberea-A J. Halle M. Shatunov A. B. nnemann C. Park-Y K. Goebel H. H. Ferrer I. Vicart P. Dalakas M. C. Goldfarb L. G. A. series of. West European. patients with. severe cardiac. skeletal myopathy. associated with. a. de novo R4. mutation W. in desmin. 2004 251 143 9 - 71.
Restrictive cardiomyopathy with atrioventricular conduction block resulting from a desmin mutation. International Journal of CardiologyPruszczyk P. Kostera-Pruszczyk A. Shatunov A. Goudeau B. Dramiñska A. Takeda K. Sambuughin N. Vicart P. Strelkov S. V. Goldfarb L. G. Kaminska A. 2007 117 244 53 - 72.
Desmin mutation responsible for idiopathic dilated cardiomyopathy. CirculationLi D. Tapscoft T. Gonzalez O. Burch P. E. MA Quiñones Zoghbi. W. A. Hill R. Bachinski L. L. Mann D. L. Roberts R. 1999 100 461 4 - 73.
Frequency and clinical characteristics of dilated cardiomyopathy caused by desmin gene mutation in a Japanese population. European Heart JournalMiyamoto Y. 2001 22 2284 9 - 74.
Neuromuscul DisordDalakas M. C. Dagvadorj A. Goudeau B. Park-Y K. Takeda K. Simon-Casteras M. Vasconcelos O. Sambuughin N. Shatunov A. Nagle J. W. Sivakumar K. Vicart P. Goldfarb L. G. Progressive skeletal. myopathy a. phenotypic variant. of desmin. myopathy associated. with desmin. mutations 2003 13 252 8 - 75.
Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. BrainMuntoni F. 2006 129 1260 8 - 76.
Mol Biol CellConover G. M. Henderson S. N. Gregorio C. C. A. myopathy-linked desmin. mutation perturbs. striated muscle. actin filament. architecture 2009 20 834 45 - 77.
Cardiovascular lesions and skeletal myopathy in mice lacking desmin. Dev. Biol.Li Z. Colucci-Guyon E. Pinçon-Raymond M. Mericskay M. Pournin S. Paulin D. Babinet C. 1996 175 362 6 - 78.
Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J. Cell Biol.Milner D. J. Weitzer G. Tran D. Bradley A. Capetanaki Y. 1996 134 1255 70 - 79.
Hearts from mice lacking desmin have a myopathy with impaired active force generation and unaltered wall compliance. Cardiovasc. Res.Balogh J. Merisckay M. Li Z. Paulin D. Arner A. 2002 53 439 50 - 80.
Trends Cardiovasc. Med.Capetanaki Y. Desmin cytoskeleton. a. potential regulator. of muscle. mitochondrial behavior. function 2002 12 339 48 - 81.
Desmin cytoskeleton linked to muscle mitochondrial distribution and respiratory function. J. Cell Biol.Milner D. J. Mavroidis M. Weisleder N. Capetanaki Y. 2000 150 1283 98 - 82.
Desmin is essential for the tensile strength and integrity of myofibrils but not for myogenic commitment, differentiation, and fusion of skeletal muscle. J. Cell Biol.Li Z. Mericskay M. Agbulut O. Butler-Browne G. Carlsson L. Thornell L. E. Babinet C. Paulin D. 1997 139 129 44 - 83.
Mouse model of desmin-related cardiomyopathy. CirculationWang X. Osinska H. Dorn G. W. Nieman M. Lorenz J. N. Gerdes A. M. Witt S. Kimball T. Gulick J. Robbins J. 2001 103 2402 7 - 84.
Structure and modifications of the junior chaperone alpha-crystallin. From lens transparency to molecular pathology. Eur. J. Biochem.Groenen P. J. Merck K. B. de Jong W. W. Bloemendal H. 1994 225 1 19 - 85.
Alpha B-crystallin is expressed in non-lenticular tissues and accumulates in Alexander’s disease brain. CellIwaki T. Kume-Iwaki A. Liem R. K. Goldman J. E. 1989 57 71 8 - 86.
Biochem Biophys Res CommunBhat S. P. Nagineni C. N. alpha B. subunit of. lens-specific protein. alpha-crystallin is. present in. other ocular. non-ocular tissues. 1989 158 319 25 - 87.
Biochem.Longoni S. James P. Chiesi M. Cardiac alpha-crystallin. I. Isolation identification Mol. Cell 1990 99 113 20 - 88.
Fiber-type-specific alphaB-crystallin distribution and its shifts with T(3) and PTU treatments in rat hindlimb muscles. J. Appl. Physiol.Atomi Y. Toro K. Masuda T. Hatta H. 2000 88 1355 64 - 89.
J. Alpha-B crystallin in the normal human myocardium and cardiac conducting system. J. Pathol.Leach I. H. Tsang M. L. Church R. J. Lowe J. Alpha-B crystallin. in the. normal human. myocardium cardiac conducting. system 1994 173 255 60 - 90.
AlphaB-crystallin interacts with intermediate filaments in response to stress. J Cell SciDjabali K. de Néchaud B. Landon F. MM Portier Alpha. 1997 Pt 21):2759-69. - 91.
Nicholl ID, Quinlan RA. Chaperone activity of alpha-crystallins modulates intermediate filament assembly. Embo J.1994 13 945 53 - 92.
Effects of site-directed mutations on the chaperone-like activity of alphaB-crystallin. J Biol ChemPlater M. L. Goode D. MJ Crabbe 1996 271 28558 66 - 93.
Alpha-crystallin can function as a molecular chaperone. Proc. Natl. Acad. Sci. U.S.A.Horwitz J. 1992 89 10449 53 - 94.
Chaperone-like activity and quaternary structure of alpha-crystallin. J Biol ChemRaman B. Rao C. M. 1994 269 27264 8 - 95.
Site-directed spin labeling study of subunit interactions in the alpha-crystallin domain of small heat-shock proteins. Comparison of the oligomer symmetry in alphaA-crystallin, HSP 27, and HSP 16.3. J Biol ChemBerengian A. R. Parfenova M. Mchaourab H. S. 1999 274 6305 14 - 96.
Coordinate and independent regulation of alpha B-crystallin and hsp27 expression in response to physiological stress. J. Cell. Physiol.Head M. W. Corbin E. Goldman J. E. 1994 159 41 50 - 97.
Crystal structure of R120G disease mutant of human αB-crystallin domain dimer shows closure of a groove. J. Mol. Biol.Clark A. R. CE Naylor Bagnéris. C. Keep N. H. Slingsby C. 2011 408 118 34 - 98.
Proc. Natl. Acad. Sci. U.S.A.Bova M. P. Yaron O. Huang Q. Ding L. Haley D. A. Stewart P. L. Horwitz J. Mutation R1. in G. alpha B-crystallin. which is. linked to. a. desmin-related myopathy. results in. an irregular. structure defective chaperone-like. function 1999 96 6137 42 - 99.
Febs J.Treweek T. M. Rekas A. Lindner R. A. MJ Walker Aquilina. J. A. Robinson C. V. Horwitz J. MD Perng Quinlan. R. A. Carver J. A. R1 alpha G. B-crystallin promotes. the unfolding. of reduced. alpha-lactalbumin is inherently. unstable 2005 272 711 24 - 100.
Intermediate filament interactions can be altered by HSP27 and alphaB-crystallin. J Cell SciMD Perng Cairns. L. van Den I. Jssel P. Prescott A. Hutcheson A. M. Quinlan R. A. 1999 Pt 13):2099-112. - 101.
Desmin aggregate formation by R120G alphaB-crystallin is caused by altered filament interactions and is dependent upon network status in cells. Mol Biol CellMD Perng Wen. S. F. van den I. Jssel P. Prescott A. R. Quinlan R. A. 2004 15 2335 46 - 102.
Am. J. Hum. Genet.Berry V. Francis P. MA Reddy Collyer. D. Vithana E. Mac Kay. I. Dawson G. Carey A. H. Moore A. Bhattacharya S. S. Quinlan R. A. Alpha-B crystallin. gene . C. R. Y. A. B. mutation causes. dominant congenital. posterior polar. cataract in. humans 2001 69 1141 5 - 103.
Invest. Ophthalmol. Vis. Sci.Liu Y. Zhang X. Luo L. Wu M. Zeng R. Cheng G. Hu B. Liu B. Liang J. J. Shang F. A. novel alpha. B-crystallin mutation. associated with. autosomal dominant. congenital lamellar. cataract 2006 47 1069 75 - 104.
Identification of a CRYAB mutation associated with autosomal dominant posterior polar cataract in a Chinese family. Invest. Ophthalmol. Vis. Sci.Liu M. Ke T. Wang Z. Yang Q. Chang W. Jiang F. Tang Z. Li H. Ren X. Wang X. Wang T. Li Q. Yang J. Liu J. Wang Q. K. 2006 47 3461 6 - 105.
Crystallin gene mutations in Indian families with inherited pediatric cataract. Mol. Vis.Devi R. R. Yao W. Vijayalakshmi P. Sergeev Y. V. Sundaresan P. Hejtmancik J. F. 2008 14 1157 70 - 106.
Safieh LA, Khan AO, Alkuraya FS. Identification of a novel CRYAB mutation associated with autosomal recessive juvenile cataract in a Saudi family. Mol. Vis.2009 15 980 4 - 107.
Mol. Vis.Chen Q. Ma Yan J. Mothobi M. ME Liu Y. Zheng F. A. novel mutation. in C. R. Y. A. B. associated with. autosomal dominant. congenital nuclear. cataract in. a. Chinese family. 2009 15 1359 65 - 108.
Myofibrillar myopathy caused by novel dominant negative alpha B-crystallin mutations. Ann. Neurol.Selcen D. Engel A. G. 2003 54 804 10 - 109.
Infantile muscular dystrophy in Canadian aboriginals is an αB-crystallinopathy. Ann. Neurol.Del Bigio M. R. Chudley A. E. Sarnat H. B. Campbell C. Goobie S. Chodirker B. N. Selcen D. 2011 69 866 71 - 110.
Infantile onset myofibrillar myopathy due to recessive CRYAB mutations. Neuromuscul DisordForrest K. M. L. Al-Sarraj S. Sewry C. Buk S. Tan S. V. Pitt M. Durward A. Mc Dougall M. Irving M. Hanna M. G. Matthews E. Sarkozy A. Hudson J. Barresi R. Bushby K. Jungbluth H. Wraige E. 2011 21 37 40 - 111.
Neuromuscul DisordReilich P. Schoser B. Schramm N. Krause S. Schessl J. Kress W. Müller-Höcker J. Walter M. C. Lochmüller H. The p. G1 mutation S. of the. alpha-B crystallin. gene . C. R. Y. A. B. causes late-onset. distal myopathy. 2010 20 255 9 - 112.
alphaB-crystallin mutation in dilated cardiomyopathies: low prevalence in a consecutive series of 200 unrelated probands. Biochem Biophys Res CommunPilotto A. Marziliano N. Pasotti M. Grasso M. Costante A. M. Arbustini E. alpha 2006 346 1115 7 - 113.
Alpha B-crystallin mutation in dilated cardiomyopathy. Biochem Biophys Res CommunInagaki N. Hayashi T. Arimura T. Koga Y. Takahashi M. Shibata H. Teraoka K. Chikamori T. Yamashina A. Kimura A. 2006 342 379 86 - 114.
Neuromuscul DisordSacconi S. Féasson L. Antoine J. C. Pécheux C. Bernard R. Cobo A. M. Casarin A. Salviati L. Desnuelle C. Urtizberea A. A. novel C. R. Y. A. B. mutation resulting. in multisystemic. disease 2012 22 66 72 - 115.
Nat. Genet.Vicart P. Caron A. Guicheney P. Li Z. Prévost M. C. Faure A. Chateau D. Chapon F. Tomé F. Dupret J. M. Paulin D. Fardeau M. A. missense mutation. in the. alpha B-crystallin. chaperone gene. causes a. desmin-related myopathy. 1998 20 92 5 - 116.
Structural and functional consequences of the mutation of a conserved arginine residue in alphaA and alphaB crystallins. J Biol ChemKumar L. V. Ramakrishna T. Rao C. M. 1999 274 24137 41 - 117.
The cardiomyopathy and lens cataract mutation in alphaB-crystallin alters its protein structure, chaperone activity, and interaction with intermediate filaments in vitro. J Biol ChemMD Perng Muchowski. P. J. van Den I. Jssel P. Wu G. J. Hutcheson A. M. Clark J. I. Quinlan R. A. 1999 274 33235 43 - 118.
Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ. Res.Wang X. Osinska H. Klevitsky R. Gerdes A. M. Nieman M. Lorenz J. Hewett T. Robbins J. 2001 89 84 91 - 119.
Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc. Natl. Acad. Sci. U.S.A.Sanbe A. Osinska H. Saffitz J. E. Glabe C. G. Kayed R. Maloyan A. Robbins J. 2004 101 10132 6 - 120.
Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy. CirculationMaloyan A. Sanbe A. Osinska H. Westfall M. Robinson D. Imahashi-I K. Murphy E. Robbins J. 2005 112 3451 61 - 121.
Nuclear import of {alpha}B-crystallin is phosphorylation-dependent and hampered by hyperphosphorylation of the myopathy-related mutant R120G. J Biol ChemEngelsman den. J. Gerrits D. de Jong W. W. Robbins J. Kato K. Boelens W. C. 2005 280 37139 48 - 122.
PLoS ONEAndley U. P. Hamilton P. D. Ravi N. Weihl C. C. A. knock-in mouse. model for. the R1. mutation G. of α. B-crystallin recapitulates. human hereditary. myopathy cataracts P. Lo 2011 e17671. - 123.
BiochemistrySimon S. Michiel M. Skouri-Panet F. Lechaire J. P. Vicart P. Tardieu A. Residue R1. is essential. for the. quaternary structure. functional integrity. of human. alpha B-crystallin. 2007 46 9605 14 - 124.
Truncation of alphaB-crystallin by the myopathy-causing Q151X mutation significantly destabilizes the protein leading to aggregate formation in transfected cells. J Biol ChemHayes V. H. Devlin G. Quinlan R. A. 2008 283 10500 12 - 125.
Cytoskeletal disruption and small heat shock protein translocation immediately after lengthening contractions. Am. J. Physiol., Cell Physiol.Koh T. J. Escobedo J. 2004 C713 22 - 126.
The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J Biol ChemKamradt M. C. Chen F. Sam S. Cryns V. L. 2002 277 38731 6 - 127.
Mol Biol CellLi-C D. W. Liu-P J. Mao-W Y. Xiang H. Wang J. Ma -Y W. Dong Z. Pike H. M. Brown R. E. Reed J. C. Calcium-activated R. A. F. M. E. K. E. R. K. signaling pathway. mediates p53-dependent. apoptosis is abrogated. by alpha. B-crystallin through. inhibition of. R. A. S. activation 2005 16 4437 53 - 128.
Adhikari AS, Singh BN, Rao KS, Rao CM. αB-crystallin, a small heat shock protein, modulates NF-κB activity in a phosphorylation-dependent manner and protects muscle myoblasts from TNF-α induced cytotoxicity. Biochim. Biophys. Acta2011 1813 1532 42 - 129.
Brady JP, Garland DL, Green DE, Tamm ER, Giblin FJ, Wawrousek EF. AlphaB-crystallin in lens development and muscle integrity: a gene knockout approach. Invest. Ophthalmol. Vis. Sci.2001 42 2924 34 - 130.
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest.Moyano J. V. Evans J. R. Chen F. Lu M. ME Werner Yehiely. F. Diaz L. K. Turbin D. Karaca G. Wiley E. Nielsen T. O. Perou C. M. Cryns V. L. Alpha 2006 116 261 70 - 131.
B-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells. Am J PatholGoplen D. Bougnaud S. Rajcevic U. Bøe S. O. Skaftnesmo K. O. Voges J. Enger P. Ø. Wang J. Tysnes B. B. Laerum O. D. Niclou S. Bjerkvig R. α. 2010 177 1618 28 - 132.
Involvement during heart ischemia. Mol. Cell. Biochem.Chiesi M. Longoni S. Limbruno U. Cardiac alpha-crystallin. I. I. I. 1990 97 129 36 - 133.
The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Naturevan Noort J. M. van Sechel A. C. Bajramovic J. J. Ouagmiri el M. Polman C. H. Lassmann H. Ravid R. 1995 375 798 801 - 134.
Expression of alpha B-crystallin in Alzheimer’s disease. Acta Neuropathol.Renkawek K. CE Voorter Bosman. G. J. van Workum F. P. de Jong W. W. 1994 87 155 60 - 135.
Distinct chaperone mechanisms can delay the formation of aggresomes by the myopathy-causing R120G alphaB-crystallin mutant. Hum. Mol. Genet.Chávez Zobel. A. T. Loranger A. Marceau N. Thériault J. R. Lambert H. Landry J. 2003 12 1609 20 - 136.
PLoS ONEHishiya A. Salman M. N. Carra S. Kampinga H. H. Takayama S. B. A. G. directly interacts. with mutated. alpha B-crystallin. to suppress. its aggregation. toxicity P. Lo 2011 e16828. - 137.
Regulation of the levels of small heat-shock proteins during differentiation of C2C12 cells. Exp Cell ResIto H. Kamei K. Iwamoto I. Inaguma Y. Kato K. 2001 266 213 21 - 138.
Muscle develops a specific form of small heat shock protein complex composed of MKBP/HSPB2 and HSPB3 during myogenic differentiation. J Biol ChemSugiyama Y. Suzuki A. Kishikawa M. Akutsu R. Hirose T. MM Waye Tsui. S. K. Yoshida S. Ohno S. 2000 275 1095 104 - 139.
Singh BN, Rao KS, Rao CM. Ubiquitin-proteasome-mediated degradation and synthesis of MyoD is modulated by alphaB-crystallin, a small heat shock protein, during muscle differentiation. Biochim. Biophys. Acta2010 1803 288 99 - 140.
J. Neurol.Reilich P. Krause S. Schramm N. Klutzny U. Bulst S. Zehetmayer B. Schneiderat P. Walter M. C. Schoser B. Lochmüller H. A. novel mutation. in the. myotilin gene. . M. Y. O. T. causes a. severe form. of limb. girdle muscular. dystrophy . A. . L. G. M. D. A. 2011 258 1437 44 - 141.
myotilin Mutation found in second pedigree with LGMD1A. Am. J. Hum. Genet.MA Hauser Conde. C. B. Kowaljow V. Zeppa G. Taratuto A. L. Torian U. M. Vance J. MA Pericak-Vance Speer. M. C. Rosa A. L. 2002 71 1428 32 - 142.
Defective myotilin homodimerization caused by a novel mutation in MYOT exon 9 in the first Japanese limb girdle muscular dystrophy 1A patient. J. Neuropathol. Exp. Neurol.Shalaby S. Mitsuhashi H. Matsuda C. Minami N. Noguchi S. Nonaka I. Nishino I. Hayashi Y. K. 2009 68 701 7 - 143.
Mutations in myotilin cause myofibrillar myopathy. NeurologySelcen D. Engel A. G. 2004 62 1363 71 - 144.
NeurologyForoud T. A. mutation in. myotilin causes. spheroid body. myopathy 2005 65 1936 40 - 145.
Lower Limb Radiology of Distal Myopathy due to the S60F Myotilin Mutation. Eur NeurolMc Neill A. Birchall D. Straub V. Goldfarb L. Reilich P. Walter M. C. Schramm N. Lochm uuml. ller H. Chinnery P. F. 2009 62 161 6 - 146.
Characterization of human palladin, a microfilament-associated protein. Mol Biol CellMykkänen O. M. Grönholm M. Rönty M. Lalowski M. Salmikangas P. Suila H. Carpén O. 2001 12 3060 73 - 147.
Parast MM, Otey CA. Characterization of palladin, a novel protein localized to stress fibers and cell adhesions. J. Cell Biol.2000 150 643 56 - 148.
BrainOlivé M. Goldfarb L. G. Shatunov A. Fischer D. Ferrer I. Myotilinopathy refining. the clinical. myopathological phenotype. 2005 128 2315 26 - 149.
Autosomal-dominant distal myopathy with a myotilin S55F mutation: sorting out the phenotype. J. Neurol. Neurosurg. Psychiatr.Berciano J. Gallardo E. Domínguez-Perles R. Gallardo E. García A. García-Barredo R. Combarros O. Infante J. Illa I. 2008 79 205 8 - 150.
Generalized muscle pseudo-hypertrophy and stiffness associated with the myotilin Ser55Phe mutation: a novel myotilinopathy phenotype? J. Neurol. Sci.Gamez J. Armstrong J. Shatunov A. Selva-O’Callaghan A. Dominguez-Oronoz R. Ortega A. Goldfarb L. Ferrer I. Olivé M. 2009 277 167 71 - 151.
Garvey SM, Miller SE, Claflin DR, Faulkner JA, Hauser MA. Transgenic mice expressing the myotilin T57I mutation unite the pathology associated with LGMD1A and MFM. Hum. Mol. Genet.2006 15 2348 62 - 152.
Myotilinopathy in a family with late onset myopathy. Neuromuscul DisordPénisson-Besnier I. Talvinen K. Dumez C. Vihola A. Dubas F. Fardeau M. Hackman P. Carpén O. Udd B. 2006 16 427 31 - 153.
Hum. Mol. Genet.Salmikangas P. Mykkänen O. M. Grönholm M. Heiska L. Kere J. Carpén O. Myotilin a. novel sarcomeric. protein with. two Ig-like. domains is. encoded by. a. candidate gene. for limb-girdle. muscular dystrophy. 1999 8 1329 36 - 154.
Characterization of mouse myotilin and its promoter. Biochem Biophys Res CommunMologni L. Moza M. MM Lalowski Carpén. O. 2005 329 1001 9 - 155.
Neuromuscul DisordSchroder R. Reimann J. Salmikangas P. Clemen C. S. Hayashi Y. K. Nonaka I. Arahata K. Carpén O. Beyond L. G. M. D. A. myotilin is. a. component of. central core. lesions nemaline rods. 2003 13 451 5 - 156.
Myotilin dynamics in cardiac and skeletal muscle cells. Cytoskeleton (Hoboken)Wang J. Dube D. K. Mittal B. Sanger J. M. Sanger J. W. 2011 68 661 70 - 157.
The Z-disc proteins myotilin and FATZ-1 interact with each other and are connected to the sarcolemma via muscle-specific filamins. J Cell SciGontier Y. Taivainen A. Fontao L. Sonnenberg A. van der Flier A. Carpén O. Faulkner G. Borradori L. 2005 118 3739 49 - 158.
Mol. Cell. Biol.Nandelstadh von. P. Ismail M. Gardin C. Suila H. Zara I. Belgrano A. Valle G. Carpén O. Faulkner G. A. class I. I. I. P. D. Z. binding motif. in the. myotilin families F. A. T. Z. binds enigma. family proteins. a. common link. for Z-disc. myopathies 2009 29 822 34 - 159.
Indications for a novel muscular dystrophy pathway. gamma-filamin, the muscle-specific filamin isoform, interacts with myotilin. J. Cell Biol.van der Ven P. F. Wiesner S. Salmikangas P. Auerbach D. Himmel M. Kempa S. Hayess K. Pacholsky D. Taivainen A. Schroder R. Carpén O. DO Furst 2000 151 235 48 - 160.
J. Mol. Biol.Witt S. H. Granzier H. Witt C. C. Labeit S. M. U. R. F. M. U. R. F. Target a. Specific Subset. of Myofibrillar. Proteins Redundantly. Towards Understanding. M. U. R. F-dependent Muscle. Ubiquitination 2005 350 713 22 - 161.
Myotilin, the limb-girdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly. Hum. Mol. Genet.Salmikangas P. van der Ven P. F. M. Lalowski M. Taivainen A. Zhao F. Suila H. Schröder R. Lappalainen P. DO Fürst Carpén. O. 2003 12 189 203 - 162.
Actin-organising properties of the muscular dystrophy protein myotilin. Exp Cell ResNandelstadh von. P. Grönholm M. Moza M. Lamberg A. Savilahti H. Carpén O. 2005 310 131 9 - 163.
Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice. Mol. Cell. Biol.Moza M. Mologni L. Trokovic R. Faulkner G. Partanen J. Carpén O. 2007 27 244 52 - 164.
Maintenance of muscle mass, fiber size, and contractile function in mice lacking the Z-disc protein myotilin. Ups. J. Med. Sci.Ochala J. Carpén O. Larsson L. 2009 114 235 41 - 165.
Target genes of neuron-restrictive silencer factor are abnormally up-regulated in human myotilinopathy. Am J PatholBarrachina M. Moreno J. Juvés S. Moreno D. Olivé M. Ferrer I. 2007 171 1312 23 - 166.
Oxidative stress in desminopathies and myotilinopathies: a link between oxidative damage and abnormal protein aggregation. Brain Pathol.Janué A. Olivé M. Ferrer I. 2007 17 377 88 - 167.
Expression of mutant ubiquitin (UBB +1) andOlive M. van Leeuwen F. W. Janué A. Moreno D. Torrejón-Escribano B. Ferrer I. 62 in myotilinopathies and desminopathies. Neuropathol Appl Neurobiol2007 - 168.
Journal of Animal ScienceGoll D. E. Neti G. Mares S. W. Thompson V. F. Myofibrillar protein. turnover The. proteasome the calpains. 2007 E19 E35. - 169.
Analysis of myotilin turnover provides mechanistic insight into the role of myotilinopathy-causing mutations. Biochem. J.Nandelstadh von. P. Soliymani R. Baumann M. Carpén O. 2011 436 113 21 - 170.
J. Cell Biol.Faulkner G. Pallavicini A. Formentin E. Comelli A. Ievolella C. Trevisan S. Bortoletto G. Scannapieco P. Salamon M. Mouly V. Valle G. Lanfranchi G. Z. A. S. P. a. new Z-band. alternatively spliced. P. D. Z-motif protein. 1999 146 465 75 - 171.
J. Cypher, a striated muscle-restricted PDZ and LIM domain-containing protein, binds to alpha-actinin-2 and protein kinase C. J Biol ChemZhou Q. Ruiz-Lozano P. ME Martone Chen. J. Cypher a. striated muscle-restricted. P. D. Z. domain-containing L. I. M. protein binds. to alpha-actinin. protein kinase. C. 1999 274 19807 13 - 172.
Mech DevelopPassier R. Richardson J. A. Olson E. N. Oracle a. novel-L P. D. Z. domain I. M. protein expressed. in heart. skeletal muscle. 2000 92 277 84 - 173.
Guy PM, Kenny DA, Gill GN. The PDZ domain of the LIM protein enigma binds to beta-tropomyosin. Mol Biol Cell1999 10 1973 84 - 174.
Purification and characterization of an alpha-actinin-binding PDZ-LIM protein that is up-regulated during muscle differentiation. J Biol ChemPomiès P. Macalma T. Beckerle M. C. 1999 274 29242 50 - 175.
J, Park J-E, Yasunami M, Hayashi H, Kimura A. A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C. J Biol ChemArimura T. Hayashi T. Terada H. Lee-Y S. Zhou Q. Takahashi M. Ueda K. Nouchi T. Hohda S. Shibutani M. Hirose M. Chen J. Park-E J. Yasunami M. Hayashi H. Kimura A. A. Cypher Z. A. S. P. mutation associated. with dilated. cardiomyopathy alters. the binding. affinity to. protein kinase. C. 2004 279 6746 52 - 176.
Echocardiographic-determined septal morphology in Z-disc hypertrophic cardiomyopathy. Biochem Biophys Res CommunTheis J. L. Bos J. M. Bartleson V. B. Will M. L. Binder J. Vatta M. Towbin J. A. Gersh B. J. Ommen S. R. MJ Ackerman 2006 351 896 902 - 177.
Ann. Neurol.Selcen D. Engel A. G. Mutations in. Z. A. S. P. define a. novel form. of muscular. dystrophy in. humans 2005 57 269 76 - 178.
J. Neurol.Cai H. Yabe I. Sato K. Kano T. Nakamura M. Hozen H. Sasaki H. Clinical pathological. genetic mutation. analysis of. sporadic inclusion. body myositis. in Japanese. people 2012 - 179.
Solution structure of ZASP PDZ domain; implications for sarcomere ultrastructure and enigma family redundancy. StructureAu Y. Atkinson R. A. Guerrini R. Kelly G. Joseph C. Martin S. R. Muskett F. W. Pallavicini A. Faulkner G. Pastore A. 2004 12 611 22 - 180.
The ZASP-like motif in actinin-associated LIM protein is required for interaction with the alpha-actinin rod and for targeting to the muscle Z-line. J Biol ChemKlaavuniemi T. Kelloniemi A. Ylänne J. 2004 279 26402 10 - 181.
Zasp/Cypher internal ZM-motif containing fragments are sufficient to co-localize with alpha-actinin- Analysis of patient mutations. Exp Cell ResKlaavuniemi T. Ylanne J. Zasp 2006 312 1299 311 - 182.
J Biol ChemFrey N. Olson E. Calsarcin- novel a. skeletal muscle-specific. member of. the calsarcin. family interacts. with multiple. Z-disc proteins. 2002 277 13998 4004 - 183.
McKeown CR, Han H-F, Beckerle MC. Molecular characterization of the Caenorhabditis elegans ALP/Enigma gene alp-1. Dev Dyn2006 235 530 8 - 184.
Zasp is required for the assembly of functional integrin adhesion sites. J. Cell Biol.Jani K. Schöck F. 2007 179 1583 97 - 185.
Post-transcriptional silencing of the Drosophila homolog of human ZASP: a molecular and functional analysis. Cell Tissue Res.Benna C. Peron S. Rizzo G. Faulkner G. Megighian A. Perini G. Tognon G. Valle G. Reggiani C. Costa R. MA Zordan 2009 337 463 76 - 186.
Muscle type-specific expression of Zasp52 isoforms in Drosophila. Gene Expr. PatternsKatzemich A. Long J. Y. Jani K. Lee B. R. Schöck F. 2011 11 484 90 - 187.
Zebrafish cypher is important for somite formation and heart development. Dev. Biol.van der Meer D. L. M. Marques I. J. Leito J. T. D. Besser J. Bakkers J. Schoonheere E. CP Bagowski 2006 299 356 72 - 188.
Characterization and in vivo functional analysis of splice variants of cypher. J Biol ChemHuang C. Zhou Q. Liang P. MS Hollander Sheikh. F. Li X. Greaser M. Shelton G. D. Evans S. Chen J. 2003 278 7360 5 - 189.
Selective deletion of long but not short Cypher isoforms leads to late-onset dilated cardiomyopathy. Hum. Mol. Genet.Cheng H. Zheng M. Peter A. K. Kimura K. Li X. Ouyang K. Shen T. Cui L. Frank D. Dalton N. D. Gu Y. Frey N. Peterson K. L. Evans S. M. Knowlton K. U. Sheikh F. Chen J. 2011 20 1751 62 - 190.
J. Ablation of Cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J. Cell Biol.Zhou Q. Chu P. H. Huang C. Cheng C. F. ME Martone Knoll. G. Shelton G. D. Evans S. Chen J. Ablation of. Cypher-L a. P. D. Z. domain I. M. Z-line protein. causes a. severe form. of congenital. myopathy 2001 155 605 12 - 191.
Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. Mol. Genet. Metab.Xing Y. Ichida F. Matsuoka T. Isobe T. Ikemoto Y. Higaki T. Tsuji T. Haneda N. Kuwabara A. Chen R. Futatani T. Tsubata S. Watanabe S. Watanabe K. Hirono K. Uese K. Miyawaki T. Bowles K. R. Bowles N. E. Towbin J. A. 2006 88 71 7 - 192.
Zaspopathy in a large classic late-onset distal myopathy family. BrainGriggs R. Vihola A. Hackman P. Talvinen K. Haravuori H. Faulkner G. Eymard B. Richard I. Selcen D. Engel A. Carpén O. Udd B. 2007 130 1477 84 - 193.
Circ Arrhythm ElectrophysiolLi Z. Ai T. Samani K. Xi Y. Tzeng-P H. Xie M. Wu S. Ge S. MD Taylor-W Dong. J. Cheng J. MJ Ackerman Kimura. A. Sinagra G. Brunelli L. Faulkner G. Vatta M. A. Z. A. S. P. missense mutation. S1 leads L. to cytoskeletal. electrical abnormalities. in a. mouse model. of cardiomyopathy. 2010 3 646 56 - 194.
Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death. Hum. Mol. Genet.Zheng M. Cheng H. Li X. Zhang J. Cui L. Ouyang K. Han L. Zhao T. Gu Y. Dalton N. D. Bang-L M. Peterson K. L. Chen J. 2009 18 701 13 - 195.
Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Circ. Res.Mochly-Rosen D. Wu G. Hahn H. Osinska H. Liron T. Lorenz J. N. Yatani A. Robbins J. Dorn G. W. 2000 86 1173 9 - 196.
PKCepsilon activation induces dichotomous cardiac phenotypes and modulates PKCepsilon-RACK interactions and RACK expression. Am. J. Physiol. Heart Circ. Physiol.Pass J. M. Zheng Y. Wead W. B. Zhang J. Li R. C. Bolli R. Ping P. P. K. 2001 H946 55 - 197.
Johnson JA, Gray MO, Chen CH, Mochly-Rosen D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J Biol Chem 1996;271:24962-6. - 198.
Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes. J. Mol. Cell. Cardiol.Liu G. S. Cohen M. V. Mochly-Rosen D. Downey J. M. 1999 31 1937 48 - 199.
Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A.Wakasaki H. Koya D. Schoen F. J. Jirousek M. R. Ways D. K. BD Hoit Walsh. R. A. King G. L. 1997 94 9320 5 - 200.
Protein kinase Cepsilon overexpression alters myofilament properties and composition during the progression of heart failure. Circ. Res.Goldspink P. H. Montgomery D. E. Walker L. A. Urboniene D. Mc Kinney R. D. Geenen D. L. Solaro R. J. Buttrick P. M. 2004 95 424 32 - 201.
Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ. Res.Takeishi Y. Ping P. Bolli R. Kirkpatrick D. L. BD Hoit Walsh. R. A. 2000 86 1218 23 - 202.
Impaired binding of ZASP/Cypher with phosphoglucomutase 1 is associated with dilated cardiomyopathy. Cardiovasc. Res.Arimura T. Inagaki N. Hayashi T. Shichi D. Sato A. Hinohara K. Vatta M. Towbin J. A. Chikamori T. Yamashina A. Kimura A. 2009 83 80 8 - 203.
In-frame deletion in the seventh immunoglobulin-like repeat of filamin C in a family with myofibrillar myopathyShatunov A. eacute M. O. Odgerel Z. Stadelmann-Nessler C. Irlbacher K. van Landeghem F. Bayarsaikhan M. Lee-S H. Goudeau B. Chinnery P. F. Straub V. Hilton-Jones D. MS Damian Kaminska. A. Vicart P. Bushby K. Dalakas M. C. Sambuughin N. Ferrer I. Goebel H. H. Goldfarb L. G. 2009 17 656 63 - 204.
Neuromuscul DisordLuan X. Hong D. Zhang W. Wang Z. Yuan Y. A. novel heterozygous. deletion-insertion mutation. (2695-27 del ins G. T. T. T. G. T. in exon. . of the. filamin C. gene causes. filaminopathy in. a. large Chinese. family 2010 20 390 6 - 205.
Mutations in the N-terminal Actin-Binding Domain of Filamin C Cause a Distal Myopathy. Am. J. Hum. Genet.Duff R. M. Tay V. Hackman P. Ravenscroft G. Mc Lean C. Kennedy P. Steinbach A. Schöffler W. van der Ven P. F. M. DO Fürst Song. J. Djinović-Carugo K. Penttilä S. Raheem O. Reardon K. Malandrini A. Gambelli S. Villanova M. Nowak K. J. Williams D. R. Landers J. E. Brown R. H. Jr Udd B. Laing N. G. 2011 2011 1 12 - 206.
Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency. NeurologyGuergueltcheva V. Peeters K. Baets J. Ceuterick-de Groote. C. Martin J. J. Suls A. De Vriendt E. Mihaylova V. Chamova T. Almeida-Souza L. Ydens E. Tzekov C. Hadjidekov G. Gospodinova M. Storm K. Reyniers E. Bichev S. van der Ven P. F. M. DO Furst Mitev. V. Lochmuller H. Timmerman V. Tournev I. De Jonghe P. Jordanova A. 2011 - 207.
The pathomechanism of filaminopathy: altered biochemical properties explain the cellular phenotype of a protein aggregation myopathy. Hum. Mol. Genet.Lowe T. Kley R. A. van der Ven P. F. M. Himmel M. Huebner A. Vorgerd M. DO Furst 2007 16 1351 8 - 208.
Mapping of two genes encoding isoforms of the actin binding protein ABP-280, a dystrophin like protein, to Xq28 and to chromosome 7. Hum. Mol. Genet.Maestrini E. Patrosso C. Mancini M. Rivella S. Rocchi M. Repetto M. Villa A. Frattini A. Zoppè M. Vezzoni P. 1993 2 761 6 - 209.
GenomicsGorlin J. B. Henske E. Warren S. T. Kunst C. B. D. apos Urso. M. Palmieri G. Hartwig J. H. Bruns G. Kwiatkowski D. J. Actin-binding protein. . A. B. P-28 filamin gene. . F. L. N. maps telomeric. to the. color vision. locus . R. G. C. P. centromeric to. G. P. D. in Xq2. 1993 17 496 8 - 210.
Molecular cloning of human ABPL, an actin-binding protein homologue. Biochem Biophys Res CommunXie Z. Xu W. Davie E. W. Chung D. W. 1998 251 914 9 - 211.
Human beta-filamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ib alpha. J Biol ChemTakafuta T. Wu G. X. Murphy G. F. Shapiro S. S. 1998 273 17531 8 - 212.
BloodXu W. F. Xie Z. W. Chung D. W. Davie E. W. A. novel human. actin-binding protein. homologue that. binds to. platelet glycoprotein. Ib alpha. 1998 92 1268 76 - 213.
J. Cell Biol.Thompson T. G. Chan Y. M. AA Hack Brosius. M. Rajala M. Lidov H. G. Mc Nally E. M. Watkins S. Kunkel L. M. Filamin . . F. L. N2 muscle-specific A. sarcoglycan interacting. protein 2000 148 115 26 - 214.
Filamin C interacts with the muscular dystrophy KY protein and is abnormally distributed in mouse KY deficient muscle fibres. Hum. Mol. Genet.Beatham J. Romero R. Townsend S. K. M. Hacker T. van der Ven P. F. M. Blanco G. 2004 13 2863 74 - 215.
Structural and functional aspects of filamins. Biochim. Biophys. Actavan der Flier A. Sonnenberg A. 2001 1538 99 117 - 216.
The limits of promiscuity: Isoform-specific dimerization of filamins. BiochemistryHimmel M. van der Ven P. F. M. Stocklein W. DO Furst 2003 42 430 9 - 217.
Unusual splicing events result in distinct Xin isoforms that associate differentially with filamin c and Mena/VASP. Exp Cell Resvan der Ven P. F. M. Ehler E. Vakeel P. Eulitz S. Schenk J. A. Milting H. Micheel B. DO Fürst 2006 312 2154 67 - 218.
J Biol ChemFaulkner G. Pallavicini A. Comelli A. Salamon M. Bortoletto G. Ievolella C. Trevisan S. Kojic S. Dalla Vecchia. F. Laveder P. Valle G. Lanfranchi G. F. A. T. Z. a. filamin actinin telethonin-binding protein. of the. Z-disc of. skeletal muscle. 2000 275 41234 42 - 219.
Proc. Natl. Acad. Sci. U.S.A.Takada F. Vander Woude. D. L. Tong H. Q. Thompson T. G. Watkins S. C. Kunkel L. M. Beggs A. H. Myozenin an. alpha-actinin gamma-filamin-binding protein. of skeletal. muscle Z. lines 2001 98 1595 600 - 220.
Mol Biol CellZhang M. Liu J. Cheng A. De Young S. M. Saltiel A. R. Identification of. C. A. P. as costameric a. protein that. interacts with. filamin C. 2007 18 4731 40 - 221.
Novel interactions of ankyrins-G at the costameres: The muscle-specific Obscurin/Titin-Binding-related Domain (OTBD) binds plectin and filamin C. Exp Cell ResMaiweilidan Y. Klauza I. Kordeli E. 2011 317 724 36 - 222.
Holmes WB, Moncman CL. Nebulette interacts with filamin C. Cell Motil. Cytoskeleton2008 65 130 42 - 223.
Mol. Cell. Biol.Dalkilic I. Schienda J. Thompson T. G. Kunkel L. M. Loss of. Filamin C. . F. L. Nc Results. in Severe. Defects in. Myogenesis Myotube Structure. 2006 26 6522 34 - 224.
Dev. Biol.Fujita M. Mitsuhashi H. Isogai S. Nakata T. Kawakami A. Nonaka I. Noguchi S. Hayashi Y. K. Nishino I. Kudo A. Filamin C. plays an. essential role. in the. maintenance of. the structural. integrity of. cardiac skeletal muscles. revealed by. the medaka. mutant zacro. 2011 2011 1 11 - 225.
Genome-wide Studies of Copy Number Variation and Exome Sequencing Identify Rare Variants in BAG3 as a Cause of Dilated Cardiomyopathy. Am. J. Hum. Genet.Norton N. Li D. MJ Rieder Siegfried. JD Rampersaud E. Züchner S. Mangos S. Gonzalez-Quintana J. Wang L. Mc Gee S. Reiser J. Martin E. Nickerson D. A. Hershberger R. E. 2011 88 273 82 - 226.
Hum. Mutat.Arimura T. Ishikawa T. Nunoda S. Kawai S. Kimura A. Dilated cardiomyopathy-associated. B. A. G. mutations impair. Z-disc assembly. enhance sensitivity. to apoptosis. in cardiomyocytes. 2011 32 1481 91 - 227.
BAG3-related myofibrillar myopathy in a Chinese family. Clin. Genet.Lee H. Cherk S. Chan S. Wong S. Tong T. Ho W. Chan A. Lee K. Mak C. B. A. 2012 81 394 8 - 228.
Am J PatholHomma S. Iwasaki M. Shelton G. D. Engvall E. Reed J. C. Takayama S. B. A. G. deficiency results. in fulminant. myopathy early lethality. 2006 169 761 73 - 229.
Cell Death DisRosati A. Graziano V. De Laurenzi V. Pascale M. Turco M. C. B. A. G. multifaceted a. protein that. regulates major. cell pathways. 2011 e141. - 230.
Circ. Res.Hishiya A. Kitazawa T. Takayama S. B. A. G. Hsc interact with. actin capping. protein Cap. Z. to maintain. myofibrillar integrity. under mechanical. stress 2010 107 1220 31 - 231.
Mechanisms of skeletal muscle injury and repair revealed by gene expression studies in mouse models. J. Physiol. (Lond.)Warren G. L. Summan M. Gao X. Chapman R. Hulderman T. Simeonova P. P. 2007 582 825 41 - 232.
Skeletal muscle repair in a mouse model of nemaline myopathy. Hum. Mol. Genet.Sanoudou D. MA Corbett Han. M. Ghoddusi M. Nguyen-A M. Vlahovich T. Hardeman N. Beggs E. C. A. H. 2006 15 2603 12 - 233.
OncogeneDoong H. Price J. Kim Y. S. Gasbarre C. Probst J. Liotta L. A. Blanchette J. Rizzo K. Kohn E. C. A. I. R- B. A. G. forms an. E. G. F-regulated ternary. complex with. phospholipase C-gamma. Hsp7 Hsc7 2000 19 4385 95 - 234.
Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell BiolTakayama S. Reed J. C. 2001 E237 41 - 235.
Cancer LettersDoong H. Vrailas A. Kohn E. C. What’s in. the’B A. G’?-a functional. domain analysis. of the. B. A. G. family proteins. 2002 2002 25 32 - 236.
J, Lambert H, Landry J. HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. J Biol ChemCarra S. Seguin S. J. Lambert H. Landry J. Hsp B. chaperone activity. toward poly. Q)-containing proteins. depends on. its association. with Bag. stimulator a. of macroautophagy. 2008 283 1437 44 - 237.
An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J Biol ChemTakayama S. Xie Z. Reed J. C. 1999 274 781 6 - 238.
Molecular chaperones and the art of recognizing a lost cause. Nat Cell BiolMc Clellan A. J. Frydman J. 2001 E51 3 - 239.
OncogeneLee J. H. Takahashi T. Yasuhara N. Inazawa J. Kamada S. Tsujimoto Y. Bis a. Bcl-2-binding protein. that synergizes. with Bcl. in preventing. cell death. 1999 18 6183 90 - 240.
Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation. Neuromuscul DisordOdgerel Z. Sarkozy A. Lee-S H. Mc Kenna C. Rankin J. Straub V. Lochmüller H. Paola F. D’Amico A. Bertini E. Bushby K. Goldfarb L. G. 2010 20 438 42 - 241.
Identification of the key structural motifs involved in HspB8/HspB6-Bag3 interaction. Biochem. J.Fuchs M. Poirier D. J. Seguin S. J. Lambert H. Carra S. Charette S. J. Landry J. 2010 425 245 55 - 242.
Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann. Neurol.JD Lünemann Schmidt. J. Schmid D. Barthel K. Wrede A. Dalakas M. C. Münz C. 2007 61 476 83 - 243.
Biochem Biophys Res CommunAntoku K. Maser R. S. Scully W. J. Delach S. M. Johnson D. E. Isolation of. Bcl binding proteins. that exhibit. homology with. B. A. G. suppressor of. death domains. protein 2001 286 1003 10 - 244. Bonelli P, Petrella A, Rosati A, Romano MF, Lerose R, Pagliuca MG, Amelio T, Festa M, Martire G, Venuta S, Turco MC, Leone A. BAG3 protein regulates stress-induced apoptosis in normal and neoplastic leukocytes. Leukemia 2004;18:358-60.
- 245.
The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Lett.Liao Q. Ozawa F. Friess H. Zimmermann A. Takayama S. Reed J. C. Kleeff J. Büchler M. W. 2001 503 151 7 - 246.
Regulation by heavy metals and temperature of the human BAG-3 gene, a modulator of Hsp70 activity. FEBS Lett.Pagliuca M. G. Lerose R. Cigliano S. Leone A. 2003 541 11 5 - 247.
Light damage induced changes in mouse retinal gene expression. Exp. Eye Res.Chen L. Wu W. Dentchev T. Zeng Y. Wang J. Tsui I. Tobias J. W. Bennett J. Baldwin D. Dunaief J. L. 2004 79 239 47 - 248.
Cell Death Differ.Romano M. F. Festa M. Pagliuca G. Lerose R. Bisogni R. Chiurazzi F. Storti G. Volpe S. Venuta S. Turco M. C. Leone A. B. A. G. protein controls. B-chronic lymphocytic. leukaemia cell. apoptosis 2003 10 383 5 - 249.
Hum. Mol. Genet.Seto J. T. Lek M. Quinlan K. G. R. Houweling P. J. Zheng X. F. Garton F. Mac Arthur. D. G. Raftery J. M. Garvey S. M. MA Hauser Yang. N. Head S. I. North K. N. Deficiency of. α-actinin is associated. with increased. susceptibility to. contraction-induced damage. skeletal muscle. remodeling 2011 20 2914 27